MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Current Hematologic Malignancy Reports' source. Wed, 08 Feb 2012 17:42:00 +0100 http://www.medworm.com/index.php?rid=5649320&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk3860132537j6350%2F Content Type Journal ArticleCategory Invited CommentaryPages 1-2DOI 10.1007/s11899-011-0112-zAuthors Michael E. Rytting, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211 (Source: Current Hematologic Malignancy Reports) Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=5649320 Mon, 30 Jan 2012 16:04:36 +0100 5649320 http://www.medworm.com/index.php?rid=5639141&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F2680602314j414q5%2F Abstract  Myeloproliferative neoplasms (MPNs) are clonal disorders characterized by excessive production of mature cells. In most of the classic Philadelphia-negative MPNs—polycythemia vera (PV), essential thrombocythemia (ET), and MPN-associated myelofibrosis (MPN-MF)—oncogenic mutations affecting JAK2 or MPL lead to constitutive activation of cytokine-regulated intracellular signalling pathways. The traditional therapy for PV and ET is the prevention of thrombotic events with antiproliferative agents in association with aspirin. New drugs such as pegylated interferon and anti-JAK agents are candidates for slowing the evolution to myelofibrosis or leukemia. Conventional therapy for MPN-MF is driven by clinical needs, primarily anemia and splenomegaly. Lenalidomide and ... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=5639141 Wed, 25 Jan 2012 18:05:35 +0100 5639141 http://www.medworm.com/index.php?rid=5583494&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F284p78688680r570%2F Abstract  Chronic lymphocytic leukemia (CLL) shows a heterogeneous clinical course, which can be explained in part by prognostic factors. Most patients do not need treatment at the time of first diagnosis. The identification of prognostic factors is of major interest if strategies can be devised to treat patients according to their individual risk profile or biological subgroup. Currently, in spite of a wealth of prognostic factors, individualized treatment approaches in different genetic or risk groups are the exemption in CLL. This review summarizes the most important prognostic and predictive factors in CLL, with particular emphasis on factors affecting treatment decisions in clinical trials and routine practice. Content Type Journal ArticleCategory Chronic Lymphocyt... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=5583494 Wed, 11 Jan 2012 17:56:53 +0100 5583494 http://www.medworm.com/index.php?rid=5583495&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc233m6wn5g48q812%2F Abstract  Chronic lymphocytic leukemia (CLL) is typically a disease of older individuals. Yet most of the literature on various chemotherapeutic regimens includes patients who are 10 to 15 years younger than the median age at diagnosis of this disease. The older patient population is grossly underrepresented in clinical trials. Currently available therapies are often too toxic for this older patient population, so their efficacy is reduced. This review discusses some of the results of treatment in older patients with CLL. A discussion of factors that often affect outcome, such as comorbidities, renal function, bone marrow reserve, and infection, are also reviewed, along with quality of life. Content Type Journal ArticleCategory Chronic Lymphocytic Leukemia (S O'Bri... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=5583495 Tue, 10 Jan 2012 16:49:22 +0100 5583495 http://www.medworm.com/index.php?rid=5583496&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F9q6827k504v70936%2F This article reviews the immune defect in CLL and discusses strategies aimed at repairing or circumventing this defect. In particular, it focuses on recent developments in the areas of CD40 ligand (CD40L/CD154) gene therapy, immunomodulatory agents such as lenalidomide, and adoptive transfer of T cells bearing chimeric antigen receptors. Content Type Journal ArticleCategory Chronic Lymphocytic Leukemia (S O'Brien, Section Editor)Pages 1-8DOI 10.1007/s11899-011-0106-xAuthors John C. Riches, Barts Cancer Institute, Queen Mary University of London, 3rd Floor John Vane Science Centre, Charterhouse Square, London, EC1M 6BQ UKAlan G. Ramsay, Barts Cancer Institute, Queen Mary University of London, 3rd Floor John Vane Science Centre, Charterhouse Square, London, EC1M 6BQ UKJohn G. Gribbe... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=5583496 Mon, 09 Jan 2012 19:39:48 +0100 5583496 http://www.medworm.com/index.php?rid=5553061&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F25611xt5834v6461%2F Abstract  Recently, 5-hydroxymethylcytosine (5-hmC), the 6th base of DNA, was discovered as the product of the hydroxylation of 5-methylcytosine (5-mC) by the ten-eleven translocation (TET) oncogene family members. One of them, TET oncogene family member 2 (TET2), is mutated in a variety of myeloid malignancies, including in 15% of myeloproliferative neoplasms (MPNs). Recent studies tried to go further into the biological and epigenetic function of TET2 protein and 5-hmC marks in the pathogenesis of myeloid malignancies. Although its precise function remains partially unknown, TET2 appears to be an important regulator of hematopoietic stem cell biology. In both mouse and human cells, its inactivation leads to a dramatic deregulation of hematopoiesis that ultimately triggers... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=5553061 Tue, 27 Dec 2011 06:34:18 +0100 5553061 http://www.medworm.com/index.php?rid=5516069&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk827535x0w902152%2F This article reviews the clinical and functional implications of epigenetic alterations in the pathogenesis of MPNs. Content Type Journal ArticleCategory Myeloproliferative Neoplasms (JJ Kiladjian, Section Editor)Pages 1-9DOI 10.1007/s11899-011-0105-yAuthors Su-Jiang Zhang, Human Oncology and Pathogenesis Program and Leukemia Service, Memorial Sloan-Kettering Cancer Center, Zuckerman 503, 408 East 69th Street, New York, NY 10065, USAOmar Abdel-Wahab, Human Oncology and Pathogenesis Program and Leukemia Service, Memorial Sloan-Kettering Cancer Center, Zuckerman 503, 408 East 69th Street, New York, NY 10065, USA Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211 (Source: Current Hematologic Malignancy Reports) Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=5516069 Wed, 14 Dec 2011 16:41:01 +0100 5516069 http://www.medworm.com/index.php?rid=5516068&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu7513047393tk77r%2F Abstract  The BCR/ABL-negative myeloproliferative neoplasms (MPNs) of essential thrombocythemia, polycythemia vera, and primary myelofibrosis, over the natural course of their disease, have an increasing predisposition to transform to overt acute myeloid leukemia (AML)—most appropriately referred to as MPN-blast phase (MPN-BP). Although this transformation is a rare event, once AML has occurred, it is associated with a poor response to therapy and short survival. The molecular events leading to transformation are poorly defined. Currently, no therapy other than allogeneic stem cell transplantation (ASCT) has been demonstrated to alter the natural history of this disease. Multiple therapeutic investigations are currently ongoing, including early ASCT, hypomethylating agent... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=5516068 Wed, 14 Dec 2011 16:41:01 +0100 5516068 http://www.medworm.com/index.php?rid=5450100&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw066q12814088tj7%2F Abstract  CD33, a 67-kDa glycoprotein expressed on the majority of myeloid leukemia cells as well as on normal myeloid and monocytic precursors, has been an attractive target for monoclonal antibody (mAb)–based therapy of acute myeloid leukemia (AML). Lintuzumab, an unconjugated, humanized anti-CD33 mAb, has modest single-agent activity against AML but failed to improve patient outcomes in two randomized trials when combined with conventional chemotherapy. Gemtuzumab ozogamicin, an anti-CD33 mAb conjugated to the antitumor antibiotic calicheamicin, improved survival in a subset of AML patients when combined with standard chemotherapy, but safety concerns led to US marketing withdrawal. The activity of these agents confirms that CD33 remains a viable therapeutic target for... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=5450100 Tue, 22 Nov 2011 17:59:22 +0100 5450100 http://www.medworm.com/index.php?rid=5442162&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm385653773076g86%2F This article reviews key biologic aspects of BCR-associated kinases in CLL and other B cell neoplasias, and develops perspectives for future development of this exciting new class of kinase inhibitors. Content Type Journal ArticleCategory Chronic Lymphocytic Leukemia (S O’Brien, Section Editor)Pages 1-8DOI 10.1007/s11899-011-0104-zAuthors Jan A. Burger, Department of Leukemia, Unit 428, The University of Texas M.D. Anderson Cancer Center, P.O. Box 301402, Houston, TX 77230-1402, USA Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211 (Source: Current Hematologic Malignancy Reports) Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=5442162 Mon, 21 Nov 2011 18:08:46 +0100 5442162 http://www.medworm.com/index.php?rid=5409667&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fdw2k0880j2366284%2F Abstract  Primary myelofibrosis (PMF) is a Philadelphia chromosome–negative chronic myeloproliferative neoplasm usually affecting elderly people. Median survival currently approaches 6 years, with a few patients surviving more than 20 years but others dying soon after diagnosis. In 10% to 20% of patients, PMF evolves into acute leukemia. Conventional treatment is merely palliative and does not prolong survival. The only chance for cure is allogeneic hemopoietic stem-cell transplantation (allo-HSCT), which is associated with high morbidity and mortality. Introduction of less aggressive forms of allo-HSCT and the prospect of molecular-targeted therapies has renewed interest in prognostication in PMF. The most important prognostic factors are anemia, age over 65&nbs... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=5409667 Wed, 09 Nov 2011 17:56:24 +0100 5409667 http://www.medworm.com/index.php?rid=5305191&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn830p82hm7381125%2F Abstract  Patients with primary resistant and relapsed acute myeloid leukemia (AML) are rarely cured without undergoing allogeneic stem cell transplantation. What is currently debated is whether a trial of re-induction chemotherapy prior to transplantation is beneficial. Data from multiple retrospective analyses have shown that pretreatment variables are useful in predicting response to salvage chemotherapy. For patients unlikely to respond, re-induction attempts may be detrimental, leading to added organ toxicity and possible increased tumor resistance. Allogeneic transplantation in the setting of active disease is the alternative strategy. Multiple studies have demonstrated the feasibility of this approach, but cure rates have been low with the use of traditional transpla... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=5305191 Thu, 06 Oct 2011 15:42:03 +0100 5305191 http://www.medworm.com/index.php?rid=5274882&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft5077l542rn06436%2F Abstract  Peripheral T-cell lymphomas (PTCLs) are a group of biologically heterogeneous but typically aggressive diseases. Progress in understanding and developing optimal therapies for PTCLs has been hampered by disease rarity and only relatively recent recognition of the importance of the T-cell phenotype. The International Peripheral T-cell Lymphoma Project was a large collaborative effort to provide a broader understanding of prognosis. Recently, several new therapies have shown promise in the treatment of PTCLs. Content Type Journal ArticleCategory Intermediate- and High-Grade Non-Hodgkin Lymphoma (Andre Goy, Section Editor)Pages 1-9DOI 10.1007/s11899-011-0100-3Authors Kerry J. Savage, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, BC V5Z 4E6, Ca... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=5274882 Wed, 28 Sep 2011 05:50:38 +0100 5274882 http://www.medworm.com/index.php?rid=5227256&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Faxw3v38505221154%2F Abstract  Enteropathy-associated T-cell lymphoma (EATL) is a rare non-Hodgkin lymphoma of T-cell origin. The recent 2008 World Health Organization classification of hematologic malignancies distinguishes between two types of EATL. The disease is associated with celiac disease, particularly with its late, adult onset. Currently, there are no standardized diagnostic or treatment protocols for EATL, mostly because of its rarity. Historically, the patients have been treated with anthracycline-based chemotherapy with or without surgery. The outcome of patients with EATL treated with these approaches is poor. The reported death rates in the biggest studies are approximately 80–84%, with median progression-free survival (PFS) of 3.4–6.0 months and overall survival of 7.1�... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=5227256 Mon, 12 Sep 2011 15:51:25 +0100 5227256 http://www.medworm.com/index.php?rid=5210190&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F3434u266g61m1873%2F Abstract  Follicular lymphoma (FL), the most common indolent lymphoma, typically presents in advanced-stage disease. Currently available therapy does not generally result in a curative outcome, but survival in FL has improved since the introduction of anti-CD20 monoclonal antibody immunotherapy. The goals of treatment include prolongation of survival and effective palliation of symptoms while limiting the duration of therapy to minimize adverse effects and reduce costs. Multiple rounds of treatment over many years characterize the clinical course for most patients with FL. Rituximab in combination with chemotherapy has been shown to improve overall survival in patients with FL compared with chemotherapy alone. Rituximab maintenance further improves disease control in patien... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=5210190 Fri, 09 Sep 2011 16:46:33 +0100 5210190 http://www.medworm.com/index.php?rid=5197032&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fe087615q643822x2%2F Abstract  Most non-Hodgkin lymphomas (NHL) are of B-cell origin; only about 10% are T-cell or NK-cell lymphomas. The clinical features of T/NK-cell lymphomas differ from those of B-cell lymphomas: advanced stage and extranodal disease are more common and the prognosis is worse. Several studies have confirmed that 2-[fluorine-18]fluoro-2-deoxy-D-glucose (18FDG) uptake varies among different subtypes of lymphoma, a disparity that can be explained by the differences in histology, proliferation of tumor cells, and the ratio of viable tumor and reactive cells in the environment. These observations are based on investigation of B-cell lymphomas. Positron emission tomography (PET)/computed tomography (CT) was found to be useful both at staging and at measuring the therapeutic outc... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=5197032 Sat, 03 Sep 2011 06:39:26 +0100 5197032 http://www.medworm.com/index.php?rid=5163494&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F933582256393p630%2F Abstract  Cutaneous T-cell lymphomas (CTCLs) are subdivided by lesion morphology, behavior, and surface receptors. Mycosis fungoides (MF) and Sézary syndrome (SS) are derived from CD4+ effector or central memory T-cells respectively. MF presents clinically as patches, plaques, or tumors, and SS presents with erythroderma. After MF/SS, the next most common CTCLs are CD30+ lymphoproliferative disorders: self-regressing lymphomatoid papulosis (LyP) or tumors of anaplastic large-cell lymphoma (ALCL), which express high levels of tumor necrosis factor death receptor member 8, also called CD30. Although MF is not considered to be a CD30+ lymphoproliferative disorder, MF may co-exist with LyP lesions, and MF may express CD30, especially in the setting of large-cell transformation... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=5163494 Thu, 18 Aug 2011 06:02:56 +0100 5163494 http://www.medworm.com/index.php?rid=5098744&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr503574302768536%2F Abstract  Guidelines and algorithms for the management of gastric mucosa-associated lymphoid tissue (MALT) lymphoma have been developed in the recent past, but the situation regarding nongastric MALT lymphomas is much more complicated. Owing to the heterogeneity of MALT lymphomas arising in various organs, different approaches to treatment have been applied, mostly in an uncontrolled fashion. In the recent past, for example, attempts to use antibiotic therapy in managing ocular adnexal MALT lymphomas have been reported, with response rates varying between 0% and 60% with the use of doxycycline or, more rarely, clarithromycin. Currently, antibiotic therapy remains experimental, with conflicting data and apparent geographic variations. In addition, there is no clear consensus... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=5098744 Tue, 02 Aug 2011 06:14:18 +0100 5098744 http://www.medworm.com/index.php?rid=4971180&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk5726v776jlu0471%2F Abstract  As survival rates for children treated for childhood cancers become significantly better, the focus is increasingly on determining the late effects of treatments and the best ways to monitor for them and prevent their occurrence. This review focuses on recent literature discussing the late effects of treatment in patients treated for acute myeloid leukemia and acute lymphoblastic leukemia during childhood. The late effects of therapy for childhood leukemia include secondary malignancy, cardiotoxicity, obesity, endocrine abnormalities, reproductive changes, neurocognitive deficits, and psychosocial effects. As clinicians have become more aware of the late effects of therapy, treatment regimens have been changed to decrease late effects, but patients still require l... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=4971180 Tue, 21 Jun 2011 20:55:40 +0100 4971180 http://www.medworm.com/index.php?rid=4947069&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx24m69383g002hnw%2F Abstract  Measuring the rapidity of response by PET scan and changing the treatment regimen in slow responders may lead to an improved outcome. Ongoing studies addressing this possibility have the potential to answer this question and need to be supported. Content Type Journal ArticlePages 1-2DOI 10.1007/s11899-011-0092-zAuthors James O. Armitage, The Joe Shapiro Professor of Medicine, Department of Internal Medicine, University of Nebraska Medical Center, 987680 Nebraska Medical Center, Omaha, NE 68198-7680, USA Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211 (Source: Current Hematologic Malignancy Reports) Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=4947069 Tue, 14 Jun 2011 05:55:17 +0100 4947069 http://www.medworm.com/index.php?rid=4938857&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk403131121048016%2F Abstract  The Philadelphia chromosome is the most common cytogenetic abnormality found in adult patients diagnosed with acute lymphoblastic leukemia. The result of this abnormality is the BCR-ABL protein, a constitutively active kinase involved in cell signaling and survival. When managed with multiagent chemotherapy regimens alone, patients have traditionally had an inferior outcome in terms of remission duration and overall survival when compared with patients who are Philadelphia chromosome–negative. Small-molecule tyrosine kinase inhibitors, such as imatinib and dasatinib, directly inhibit the BCR-ABL kinase, offering a targeted approach as a therapeutic option. As a result of several clinical trials with adequate follow-up, imatinib combined with chemotherapy represe... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=4938857 Fri, 10 Jun 2011 06:24:49 +0100 4938857 http://www.medworm.com/index.php?rid=4854997&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk74u035458024313%2F This article reviews the treatment approach for mediastinal lymphomas, including CHL of the nodular sclerosis subtype (CHL-NS), PMBL, and mediastinal GZL. Though several trials have evaluated different regimens with or without radiation in PMBL and CHL-NS, there is a lack of prospective experience in treating GZL because of the rarity of these tumors. Historical data indicate that they have done poorly with traditional approaches developed for the treatment of either CHL or diffuse large B-cell lymphoma. Content Type Journal ArticlePages 1-7DOI 10.1007/s11899-011-0090-1Authors Cliona Grant, Metabolism Branch, National Cancer Institute, Center for Cancer Research, National Institutes of Health, 10 Center Drive, Room 4N 115, Bethesda, MD 20892, USAKieron Dunleavy, Metabolism Branc... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=4854997 Wed, 18 May 2011 06:16:03 +0100 4854997 http://www.medworm.com/index.php?rid=4832711&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm71vngt608vxx8j3%2F Abstract  Between 80% and 90% of Hodgkin lymphoma (HL) patients can be cured with up-to-date combined-modality treatments, but patients with disease refractory to first-line therapy and those who relapse after first-line therapy still have a relatively poor prognosis. Dose intensification with stem cell support has been evaluated both to avoid relapses and to cure patients with refractory or relapsed disease. In this review, we focus on the use of high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) in first-line, second-line, and third-line therapy for HL patients. The relevance of salvage therapy before high-dose chemotherapy is discussed, as well as the role of sequential high dose chemotherapy. We also review current evidence for tandem transpl... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=4832711 Thu, 12 May 2011 16:41:19 +0100 4832711 http://www.medworm.com/index.php?rid=4814726&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fxx4059u5336x2681%2F Abstract  In recent decades, the prognosis of Hodgkin lymphoma has been substantially improved, but these successes have been restricted to younger patients and could not be translated into a major benefit for older patients, especially those with advanced-stage disease. Major problems in treating older patients include a different biology, frailty, comorbidities, and poorer tolerance of therapy. Additionally, these patients are often excluded from randomized trials, so an evidence-based standard of care is lacking. Importantly, the proportion of older patients with HL will increase over the next 50 years. Currently, ABVD (Adriamycin [doxorubicin], bleomycin, vinblastine, and dacarbazine) is considered to be the gold standard, even though it has some toxicity in older ... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=4814726 Mon, 09 May 2011 05:34:57 +0100 4814726 http://www.medworm.com/index.php?rid=4745345&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F73873n1064026n25%2F Abstract  Advances in the treatment of Hodgkin lymphoma since about 1970 have led to a remarkable improvement in the long-term outcomes of what was once considered an incurable disease. The prolonged survival of cured patients has revealed new issues concerning the toxicity of successful therapy, however, including an increased risk of secondary malignancies and end-organ damage such as heart disease. This concern has led to the clinical research question of whether the de-escalation of treatment intensity could allow high cure rates to continue with less long-term toxicity. In young patients with favorable early-stage disease, the challenge has been to use systemic therapy while omitting radiation therapy as part of the initial treatment. This review briefly summarizes pas... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=4745345 Tue, 19 Apr 2011 07:13:31 +0100 4745345 http://www.medworm.com/index.php?rid=4665703&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fwnv9288754761140%2F Abstract  As of 2011, the choice of tyrosine kinase inhibitor (TKI) for the patient with newly diagnosed chronic-phase chronic myelogenous leukemia (CP-CML) is no longer limited to imatinib but can be expanded to include nilotinib and dasatinib. Since 2000, imatinib has demonstrated remarkable efficacy in the majority of chronic-phase patients. Nilotinib and dasatinib, both more potent TKIs, are likely to produce quicker and deeper molecular responses, but there are no established criteria for choosing the best inhibitor for each patient. We now need to establish clearly defined recommendations to address this new stage, in which individualized therapy in the front-line should become a reality. Likely to be paramount in this setting are assays that directly assess the effic... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=4665703 Tue, 29 Mar 2011 17:32:41 +0100 4665703 http://www.medworm.com/index.php?rid=4645566&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F5162280135w471p8%2F Abstract  Myelodysplastic syndromes (MDS) represent a spectrum of bone marrow failure with variable outcome. Patients with “lower-risk” disease have an expected median survival measured in years, and a low risk of leukemia progression. Patients with “higher-risk” MDS, on the other hand, have expected survival measured in months without treatment and rapid leukemia progression. The outcome of those distinct groups can be explained by different underlying disease biology. In clinical practice, patients are stratified into risk groups based on prognostic models, most commonly the International Prognostic Scoring System (IPSS). In higher-risk disease, the standard of care is hypomethylating agents to extend survival and suppress leukemia potential, and consideration of ... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=4645566 Fri, 25 Mar 2011 18:49:40 +0100 4645566 http://www.medworm.com/index.php?rid=4578671&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F347mx2jt02084363%2F Abstract  Treatment of myeloma has changed significantly in the past decade as a result of better understanding of disease biology, more effective treatments, and improved supportive care. Autologous stem cell transplantation (SCT) is an effective treatment for myeloma and remains a critical component in its management. Given the potential impact of therapy on stem cell collection, initial treatment decisions in myeloma still depend on the patient’s transplant eligibility. The goals of initial therapy remain rapid disease control allowing for reversal of disease complications, as well as reduction in the risk of early death—all with minimal toxicity. The introduction of new drugs such as thalidomide, bortezomib, and lenalidomide has enabled us to achieve this goal, and ... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=4578671 Thu, 10 Mar 2011 17:11:54 +0100 4578671 http://www.medworm.com/index.php?rid=4562221&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F9618228175434342%2F Abstract  Accumulation of excessive amounts of iron in vulnerable organs and tissues, together with elevated plasma and intracellular concentrations of reactive iron molecules, are likely to be harmful to some patients with myelodysplastic syndromes (MDS) who have received numerous red blood cell transfusions. But what is the real magnitude of risks related to iron overload in MDS, and how strong is the evidence that reducing total body iron and labile plasma iron through treatment with chelating drugs is beneficial to patients? Available data can be interpreted in different ways, and as a result, these topics continue to be areas of heated debate among physicians who care for patients with MDS. Using the traditional but rarely employed format of a classical dialogue, I exp... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=4562221 Fri, 04 Mar 2011 11:06:38 +0100 4562221 http://www.medworm.com/index.php?rid=4562222&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F08w6k743670p4rm1%2F Abstract  Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder that is characterized by the presence of a fusion oncogene, BCR-ABL, which encodes a protein with constitutive tyrosine kinase activity. This activity causes excessive production of myeloid cells and their premature release into the circulation. The discovery of tyrosine kinase inhibitors marked a major advance in CML therapy, but these drugs cannot eradicate the disease because they are unable to kill the most primitive, quiescent leukemic stem cells. This review discusses current research in CML and attractive targets that have emerged with potential for eradicating the disease. Several new targets have recently been investigated as potential modulators in myeloid leukemia pathogenesis, inclu... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=4562222 Fri, 04 Mar 2011 11:06:36 +0100 4562222 http://www.medworm.com/index.php?rid=4541747&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F762k04866u337703%2F Abstract  Molecular monitoring is a key component of the management of patients with chronic myeloid leukemia. The current recommendation is that molecular monitoring be performed in place of cytogenetic assessment when a major molecular response (MMR) is achieved. With the more potent kinase inhibitors nilotinib and dasatinib now approved as front-line therapy, more patients will achieve an MMR and will benefit from molecular monitoring. There is a strong correlation between certain BCR-ABL1 levels and the cytogenetic response, which means that molecular monitoring may act as a surrogate for cytogenetic response, but only if the BCR-ABL1 values are converted to the international reporting scale. Furthermore, improvements in the limit of BCR-ABL1 detection and reduction of in... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=4541747 Mon, 28 Feb 2011 16:48:14 +0100 4541747 http://www.medworm.com/index.php?rid=4541748&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm11786198768l753%2F Abstract  Melphalan plus prednisone (MP) has long been considered the gold-standard treatment for elderly patients with newly diagnosed myeloma, and it still forms the backbone for combinations based on novel agents. MP plus thalidomide (MPT), bortezomib (VMP), or lenalidomide (MPR), as induction plus maintenance, have proved to be superior to MP and are currently the treatment of choice for this population. Low-dose dexamethasone in combination with thalidomide and cyclophosphamide (CTDa) or with lenalidomide can be an alternative option for these patients. The benefit of these novel agents in terms of prolonged survival is accompanied by increases in treatment-related adverse events, however, which may be particularly pronounced in older individuals. In managing these pat... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=4541748 Wed, 23 Feb 2011 23:34:36 +0100 4541748 http://www.medworm.com/index.php?rid=4513789&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh261l57x10406v7p%2F Abstract  Myelodysplastic syndromes (MDS) are clonal hematologic neoplasms that can result in cytopenias and increase the risk of leukemic transformation. The disease is characterized by several recurrent cytogenetic defects, which can affect diagnosis, prognosis, and treatment. Metaphase cytogenetics (MC) is the gold standard in karyotypic analysis in hematology. Progress in molecular analysis, including additional karyotypic tools exemplified by fluorescence in situ hybridization, comparative genomic hybridization, and more importantly, single nucleotide polymorphism array (SNP-A) analysis, has led to increased detection of chromosomal abnormalities in myeloid malignancies and improved prognostic risk stratification. SNP-A, together with MC, has also been instrumental in ... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=4513789 Mon, 21 Feb 2011 17:07:26 +0100 4513789 http://www.medworm.com/index.php?rid=4496236&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh546w2x4w4784rq7%2F Abstract  The introduction of tyrosine kinase inhibitors (TKIs) has changed the landscape of therapy for chronic myelogenous leukemia (CML). Once considered an incurable malignancy, CML now has become a manageable chronic condition. Despite the great advances that imatinib has brought to the treatment of CML, some patients still develop resistance to imatinib and other TKIs, such as dasatinib and nilotinib. Furthermore, none of the clinically available TKIs is capable of eradicating leukemia stem cells and therefore curing CML. Several new compounds have been developed in recent years in an attempt to manage TKI-resistant CML. These include third-generation TKIs (ponatinib, danusertib) and even old compounds such as omacetaxine, which were developed before imatinib and now ... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=4496236 Wed, 16 Feb 2011 06:59:34 +0100 4496236 http://www.medworm.com/index.php?rid=4496235&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh24m716237275964%2F Abstract  Multiple myeloma (MM) is an incurable malignancy of plasma cells. The introduction of thalidomide was a milestone in the treatment of MM. Thalidomide analogues termed immunomodulatory drugs (IMiDs) have been developed that are more effective and have less toxicity than thalidomide. The role of lenalidomide in relapsed MM has been well defined. This review discusses the data regarding the upfront use of lenalidomide with dexamethasone or in multidrug combinations, as well as its potential role as maintenance therapy. It also reviews our experience with pomalidomide, a new IMid with remarkable activity in relapsed, refractory MM. Content Type Journal ArticlePages 1-6DOI 10.1007/s11899-011-0077-yAuthors Martha Q. Lacy, Division of Hematology, Mayo Clinic, 200 Fi... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=4496235 Wed, 16 Feb 2011 06:59:34 +0100 4496235 http://www.medworm.com/index.php?rid=4496237&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg83753n1l7521528%2F Content Type Journal ArticlePages 1-2DOI 10.1007/s11899-011-0078-xAuthors Sagar Lonial, Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, 1365 Clifton Road, Building C, Room 4004, Atlanta, GA 30322, USA Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211 (Source: Current Hematologic Malignancy Reports) Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=4496237 Wed, 16 Feb 2011 06:59:32 +0100 4496237 http://www.medworm.com/index.php?rid=4302429&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F37375162813g44h4%2F Abstract  Burkitt lymphoma (BL) is a mature B-cell non-Hodgkin lymphoma with an aggressive clinical course. Since the advent of short, intensive, multiagent chemoimmunotherapy regimens, it has carried a favorable prognosis. BL has been rather well characterized, whereas the other lymphomas morphologically resembling it are more heterogeneous. The cases classified as atypical BL/Burkitt-like lymphoma by the 2001 World Health Organization (WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissue were thought to represent a continuum between BL and diffuse large B-cell lymphoma (DLBCL). The optimal therapeutic strategy for this provisional entity was not definitively established. However, recent incorporation of molecular genetic data into the 2008 WHO Classification ... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=4302429 Thu, 30 Dec 2010 06:52:31 +0100 4302429 http://www.medworm.com/index.php?rid=4301149&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx85t631466641061%2F This article reviews the role of hematopoietic stem cell transplantation in the treatment of diffuse large B-cell lymphoma, the incorporation of rituximab, and avenues of clinical investigation in this rapidly evolving field. Content Type Journal ArticleDOI 10.1007/s11899-010-0075-5Authors Celso Arrais Rodrigues, Centro de Oncologia, Hospital Sírio Libanês, São Paulo, BrazilPoliana Alves Patah, Centro de Oncologia, Hospital Sírio Libanês, São Paulo, BrazilYana A. S. Novis, Centro de Oncologia, Hospital Sírio Libanês, São Paulo, BrazilChitra Hosing, Department of Stem Cell Transplantation and Cell Therapy, MD Anderson Cancer Center, Houston, TX USAMarcos de Lima, Department of Stem Cell Transplantation and Cell Therapy, MD Anderson Cancer Center, 1515 Holcombe Boulevard, U... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=4301149 Wed, 29 Dec 2010 06:49:29 +0100 4301149 http://www.medworm.com/index.php?rid=4301150&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl138261447746360%2F Content Type Journal ArticleDOI 10.1007/s11899-010-0074-6Authors Susan O’Brien, Department of Leukemia, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, P.O. Box 301402, Houston, TX 77230-1402, USA Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211 (Source: Current Hematologic Malignancy Reports) Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=4301150 Tue, 28 Dec 2010 15:15:57 +0100 4301150 http://www.medworm.com/index.php?rid=4289253&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fj1x41h3534336q15%2F This article reviews the state of the art regarding these issues, with special emphasis on experts’ consensus recommendations. Content Type Journal ArticleDOI 10.1007/s11899-010-0073-7Authors Tiziano Barbui, Research Foundation, Ospedali Riuniti, Via Garibaldi 13, 24124 Bergamo, ItalyGuido Finazzi, Division of Hematology, Ospedali Riuniti, Largo Barozzi 1, 24128 Bergamo, Italy Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211 (Source: Current Hematologic Malignancy Reports) Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=4289253 Wed, 22 Dec 2010 20:23:55 +0100 4289253 http://www.medworm.com/index.php?rid=4268063&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw857r25832033j18%2F Content Type Journal ArticleDOI 10.1007/s11899-010-0072-8Authors Eric J. Feldman, Weill Medical College of Cornell University, 525 East 68th Street, New York, NY 10021, USA Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211 (Source: Current Hematologic Malignancy Reports) Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=4268063 Wed, 15 Dec 2010 16:05:36 +0100 4268063 http://www.medworm.com/index.php?rid=4268064&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F6664k546m6175x56%2F This article reviews current treatment strategies for lower-risk MDS and examines the data for selected novel agents that are available or are being developed for the treatment of this disease. Content Type Journal ArticleDOI 10.1007/s11899-010-0071-9Authors Shyamala C. Navada, Tisch Cancer Institute, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1079, New York, NY 10029, USALewis R. Silverman, Tisch Cancer Institute, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1079, New York, NY 10029, USA Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211 (Source: Current Hematologic Malignancy Reports) Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=4268064 Tue, 14 Dec 2010 13:25:38 +0100 4268064 http://www.medworm.com/index.php?rid=4268065&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh668033p1503u155%2F Abstract  Chronic lymphocytic leukemia (CLL) is a lymphoproliferative disease with significant variation in disease progression, response to therapy, and survival outcome. Deletions of 17p or mutations of TP53 have been identified as one of the poorest prognostic factors, being predictive of short time for disease progression, lack of response to therapy, short response duration, and short overall survival. The treatment of patients with CLL has improved significantly with the development of chemoimmunotherapy, but this benefit was not pronounced in patients with 17p deletion. We compare various treatment strategies used in these patients, including FCR-like chemoimmunotherapy, alemtuzumab, other antibody combinations, or novel targeted therapies with promising results. Allo... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=4268065 Mon, 13 Dec 2010 22:43:27 +0100 4268065 http://www.medworm.com/index.php?rid=4243032&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fjhghu8876325k069%2F Abstract  Myelodysplastic syndromes (MDS) are a group of heterogeneous bone marrow disorders characterized by a failure of hematopoiesis and an increased propensity for transformation to acute myeloid leukemia. Determining the prognosis of patients with MDS is essential for discerning the best therapy, which can vary from supportive care to allogeneic stem cell transplantation. The most widely used prognostic model in MDS is the International Prognostic Scoring System (IPSS), which estimates survival and risk of transformation to acute myeloid leukemia based on the percentage of blasts, karyotype, and number of cytopenias, but the IPSS has several limitations that preclude more widespread application. Over the past decade, several studies have reported on new prognostic fac... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=4243032 Mon, 06 Dec 2010 18:50:08 +0100 4243032 http://www.medworm.com/index.php?rid=4180358&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn4h631825355w10g%2F Abstract  Ever since their description as “myeloproliferative syndromes” by William Dameshek in 1951, the myeloproliferative neoplasms (MPNs) have been managed by the selective use of rather mundane, nonspecific therapies that rely on either antiplatelet effects or myelosuppression. The year 2005 ushered in a new era of drug development and discovery for the MPNs after the description of the JAK2 V617F mutation and the role this constitutively active tyrosine kinase has in MPN pathogenesis. Subsequently, multiple pharmacologic agents have begun (or are about to begin) testing for the inhibition of JAK2 in an attempt to improve the treatment of MPNs. Both primary myelofibrosis and myelofibrosis following essential thrombocythemia or polycythemia vera have been the target... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=4180358 Tue, 16 Nov 2010 07:02:03 +0100 4180358 http://www.medworm.com/index.php?rid=4176542&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx5v83u7g75016110%2F Abstract  T-cell lymphomas are an uncommon and heterogeneous group of non-Hodgkin lymphomas. Historically, therapies for these diseases have been borrowed from treatments for other lymphomas. More recently, efforts have be made to identify novel agents for their activity specifically in T-cell lymphomas. A primary example of new agents with specific activity in T-cell lymphomas is the novel class of drug, histone deacetylase inhibitors. The potential activity of histone deacetylase inhibitors was discovered somewhat serendipitously, but these early discoveries were followed by some larger and more rigorous studies in T-cell lymphomas. Two compounds, vorinostat and romidepsin, are currently approved and are in clinical use for the treatment of cutaneous T-cell lymphomas. Oth... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=4176542 Mon, 15 Nov 2010 18:07:48 +0100 4176542 http://www.medworm.com/index.php?rid=4006091&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F13515vu103940612%2F Content Type Journal ArticleDOI 10.1007/s11899-010-0066-6Authors Pier Paolo Piccaluga, Department of Hematology and Oncological Sciences “L. and A. Seràgnoli”, Hematopathology Unit, S. Orsola-Malpighi Hospital, University of Bologna, Via Massarenti, 9, 40138 Bologna, ItalyClaudio Agostinelli, Department of Hematology and Oncological Sciences “L. and A. Seràgnoli”, Hematopathology Unit, S. Orsola-Malpighi Hospital, University of Bologna, Via Massarenti, 9, 40138 Bologna, ItalyAnna Gazzola, Department of Hematology and Oncological Sciences “L. and A. Seràgnoli”, Hematopathology Unit, S. Orsola-Malpighi Hospital, University of Bologna, Via Massarenti, 9, 40138 Bologna, ItalyClaudia Mannu, Department of Hematology and Oncological Sciences “L. and A. Seràgnoli”, Hematopa... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=4006091 Mon, 27 Sep 2010 16:52:42 +0100 4006091 http://www.medworm.com/index.php?rid=3889855&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp1vv454074j1nn74%2F Abstract  Although the majority of patients with Hodgkin lymphoma achieve sustained remission with frontline treatment, there is still a subset of patients with much less favorable prognosis. The current standard of care for Hodgkin lymphoma patients with relapsed or refractory disease is autologous stem cell transplantation. However, no randomized trial has compared autologous stem cell transplantation with allogeneic stem cell transplantation prospectively, and most studies comparing allogeneic stem cell transplantation with historical controls of autologous stem cell transplantation use a myeloablative conditioning reference group. With the more frequent use of reduced-intensity conditioning transplantation in recent studies, the role for allogeneic stem cell transplantat... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=3889855 Fri, 20 Aug 2010 17:06:23 +0100 3889855 http://www.medworm.com/index.php?rid=3883128&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr6l33k8202077827%2F Abstract  Although the vast majority of children with acute lymphocytic leukemia attain remission with modern therapies, an unacceptably high number will suffer a disease relapse. Both the duration of remission and the site of relapse are important prognostic factors. This review focuses on leukemic relapse isolated to sites outside the bone marrow (extramedullary sites). Data from cooperative study groups as well as large single institutions are reviewed with respect to the incidence of isolated extramedullary relapse as well as the outcome following relapse. The unique anatomic and physiologic properties of the testes and the central nervous system—the two most common sites of isolated extramedullary relapse—are discussed. Finally, the evolution of leukemia therapy is... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=3883128 Tue, 17 Aug 2010 20:37:18 +0100 3883128 http://www.medworm.com/index.php?rid=3832555&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk14537358664161l%2F In conclusion, although the IPI is somewhat effective for PTCL prognostication, novel scores that are more refined and possibly disease-specific are warranted. The validation process for several models, including clinical-pathological and molecular models, is now ongoing. Content Type Journal ArticleDOI 10.1007/s11899-010-0062-xAuthors Pier Paolo Piccaluga, Department of Hematology and Oncological Sciences “L. and A. Seràgnoli”, Hematopathology Unit, S. Orsola-Malpighi Hospital, University of Bologna, Via Massarenti, 9, 40138 Bologna, ItalyClaudio Agostinelli, Department of Hematology and Oncological Sciences “L. and A. Seràgnoli”, Hematopathology Unit, S. Orsola-Malpighi Hospital, University of Bologna, Via Massarenti, 9, 40138 Bologna, ItalyAnna Gazzola, Department of ... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=3832555 Fri, 06 Aug 2010 07:14:25 +0100 3832555 http://www.medworm.com/index.php?rid=3818687&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv8651121770n5442%2F This article discusses such novel targets for the treatment of ALL. Content Type Journal ArticleDOI 10.1007/s11899-010-0064-8Authors Margaret T. Kasner, Thomas Jefferson University 834 Chestnut Street, Suite 315 Philadelphia PA 19107 USA Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211 (Source: Current Hematologic Malignancy Reports) Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=3818687 Mon, 02 Aug 2010 19:24:33 +0100 3818687 http://www.medworm.com/index.php?rid=3796539&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr5806g84v8k8juq7%2F Abstract  Despite the high cure rates achieved with intensified primary therapies for childhood non-Hodgkin’s lymphomas (NHL), the prognosis for children with relapsed or refractory disease is poor. Optimal treatment for this group remains a challenge. Dose intensification followed by stem cell transplantation has been used in these circumstances and may provide a curative treatment option for these patients, but the number of children treated using this approach is relatively small and its effectiveness has been difficult to judge. Moreover, the limited experience is insufficient to define the patient most likely to benefit from transplantation. Likewise, the selection of autologous or allogeneic transplantation and the optimal conditioning regimen are debated. We summari... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=3796539 Mon, 26 Jul 2010 21:54:01 +0100 3796539 http://www.medworm.com/index.php?rid=3785327&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fgt21g3712312h246%2F Abstract  Acute myeloid leukemia (AML), a heterogeneous group of diseases with variable responses to the same therapy, comprises nearly a quarter of childhood acute leukemias. Although historically very few prognostic markers have been incorporated into therapeutic decision making in AML, recent advances in technology have enabled identification of numerous factors associated with disease outcome. This review provides a detailed analysis of most clinically relevant factors associated with disease outcome in childhood AML. Content Type Journal ArticleDOI 10.1007/s11899-010-0060-zAuthors Mohamed Radhi, Children’s Mercy Hospital 2401 Gillham Road Kansas City MO 64108 USASoheil Meshinchi, Fred Hutchinson Cancer Research Center 1100 Fairview Avenue North, D5-380 P.O. Box�... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=3785327 Fri, 23 Jul 2010 12:10:01 +0100 3785327 http://www.medworm.com/index.php?rid=3785328&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F0q3708hwr641jr34%2F Abstract  In the pre-imatinib era, the treatment outcome of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) was dismal. Complete remission was generally achieved only in about 50% to 60% of patients, and allogeneic hematopoietic stem cell transplantation (allo-HSCT), when feasible in younger patients, was virtually the sole curative modality. Imatinib has changed the situation dramatically, however, in combination with conventional chemotherapy or with corticosteroid alone, producing about 95% complete remission and thus increasing the number of patients undergoing allo-HSCT. Currently, the overall survival of patients who have undergone allo-HSCT exceeds 50%, and a considerable proportion of patients for whom allo-HSCT is not feasibl... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=3785328 Fri, 23 Jul 2010 12:10:00 +0100 3785328 http://www.medworm.com/index.php?rid=3774080&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F67r27u65734k3280%2F Abstract  Lymphomas represent the third most common cancer in children and adolescents. The non-Hodgkin’s lymphomas comprise a heterogeneous group of tumors, with distinct clinical and pathologic features. Although intensive multi-agent chemotherapy has made non-Hodgkin’s lymphoma one of the most curable malignancies in children and young adults, there is room for improvement in treatment, particularly for those with advanced-stage disease and those who relapse after conventional therapy. New approaches are now attempting to reduce the burden of treatment, to focus on novel and more specific biologic targets, and to improve outcomes for patients with advanced-stage disease while reducing the potential for late effects. A comprehensive review of all potential agents is b... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=3774080 Fri, 16 Jul 2010 19:48:17 +0100 3774080 http://www.medworm.com/index.php?rid=3583223&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh748581v304344t1%2F Abstract  Monoclonal antibodies targeting surface proteins on the malignant Hodgkin and Reed-Sternberg (HRS) cells are currently under intensive investigation with promising early results. Of particular interest is the CD20 antigen, because it is expressed not only on a small fraction of HRS cells but also on the benign reactive B cells in the microenvironment. The rationale of using rituximab in classic Hodgkin lymphoma (cHL) comprises several points: 1) HRS cells infrequently express CD20; 2) elimination of CD20-positive reactive B cells supporting HRS cells would deprive the malignant cells of survival signals; 3) elimination of reactive B cells may also potentially increase host immune response against HRS cells; 4) HRS stem cells express CD20. Although this rationale h... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=3583223 Wed, 19 May 2010 18:02:45 +0100 3583223 http://www.medworm.com/index.php?rid=3583224&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F1827105tq6858xq5%2F Abstract  Of the cases of non-Hodgkin lymphoma (NHL) diagnosed in children and adolescents, 10% comprise a diverse mixture of unusual B-cell or T-cell disease, some types of which are more commonly seen in adults. Understanding of these rare types of NHL comes from small pediatric case series or the adult literature. Some rare pediatric NHL is similar to adult NHL, but other types have different molecular and cytogenetic characteristics. It is important to improve understanding and treatment of these rare pediatric NHLs through international collaborative efforts. Content Type Journal ArticleDOI 10.1007/s11899-010-0055-9Authors Bhuvana A. Setty, Division of Hematology/Oncology/BMT Department of Pediatrics, Nationwide Children’s Hospital 700 Children’s Drive Columbu... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=3583224 Wed, 19 May 2010 10:58:45 +0100 3583224 http://www.medworm.com/index.php?rid=3567524&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg331143r3g704508%2F This article discusses the methods used for detecting MRD in childhood AML and ALL, the data obtained in studies correlating MRD with treatment outcome, the results of the initial trials using MRD, and the practical aspects related to the design of MRD-based clinical studies. Content Type Journal ArticleDOI 10.1007/s11899-010-0056-8Authors Dario Campana, St. Jude Children’s Research Hospital Department of Oncology 262 Danny Thomas Place Memphis TN 38105 USA Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211 (Source: Current Hematologic Malignancy Reports) Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=3567524 Fri, 14 May 2010 09:36:38 +0100 3567524 http://www.medworm.com/index.php?rid=3546260&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F7034386mw1417738%2F Abstract  Significant improvements in induction therapy for multiple myeloma have been seen over the past decade for both transplant-eligible patients and transplant-ineligible patients. The emergence of novel agents in managing myeloma has revealed new directions for clinicians to approach the disease. The first determinant is transplant eligibility. With the recognition of the prognostic impact of postinduction response on overall outcomes, the importance of the choice of optimal regimen has become more important than ever. The preference of induction therapy for transplant-eligible patients has progressively changed from the alkylator-based therapies to doublet therapies to triplet therapies incorporating immunomodulatory drugs (IMiDs) and proteasome inhibitors. The role... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=3546260 Fri, 07 May 2010 08:52:37 +0100 3546260 http://www.medworm.com/index.php?rid=3544327&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F5469158654215483%2F This article highlights the development of anti-CD30 antibodies and ADCs for relapsed or refractory classical HL. Content Type Journal ArticleDOI 10.1007/s11899-010-0053-yAuthors Kelley V. Foyil, Washington University School of Medicine, Siteman Cancer Center 660 South Euclid Box 8056 St. Louis MO 63110 USANancy L. Bartlett, Washington University School of Medicine, Siteman Cancer Center 660 South Euclid Box 8056 St. Louis MO 63110 USA Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211 (Source: Current Hematologic Malignancy Reports) Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=3544327 Thu, 06 May 2010 08:03:50 +0100 3544327 http://www.medworm.com/index.php?rid=3544328&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F48r2021762x4840j%2F Abstract  Allogeneic hematopoietic cell transplantation is curative for patients with high-risk leukemia, but disease recurrence remains a major cause of treatment failure. New tools are now available to potentially identify patients with minimal residual disease who are at high risk for treatment failure. These improvements in disease detection allow for new opportunities to prevent relapse. The transplant course can be conceptualized into the pretransplant, peritransplant, and posttransplant periods. This article discusses the differing transplant interventions aimed at reducing relapse in each of these periods, focusing on new approaches that are currently being conceived or in early-stage clinical trials. Content Type Journal ArticleDOI 10.1007/s11899-010-0051-0Auth... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=3544328 Thu, 06 May 2010 08:03:48 +0100 3544328 http://www.medworm.com/index.php?rid=3531791&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F0165g6j017w2129v%2F This article briefly reviews current primary treatment strategies for HL and examines the existing data for both new cytotoxic agents and other selected novel agents in the treatment of HL. Content Type Journal ArticleDOI 10.1007/s11899-010-0054-xAuthors David W. Dougherty, University of Rochester Medical Center James P. Wilmot Cancer Center, Division of Hematology/Oncology 601 Elmwood Avenue, Box 704 Rochester NY 14642 USAJonathan W. Friedberg, University of Rochester Medical Center James P. Wilmot Cancer Center, Division of Hematology/Oncology 601 Elmwood Avenue, Box 704 Rochester NY 14642 USA Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211 (Source: Current Hematologic Malignancy Reports) Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=3531791 Sat, 01 May 2010 07:14:22 +0100 3531791 http://www.medworm.com/index.php?rid=3492078&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk115244338h14431%2F Abstract  Hematopoietic stem cell transplantation has been an important treatment modality in the management of high-risk or relapsed childhood acute lymphoblastic leukemia. Analysis of its efficacy has been based mostly on stratification of patients by epidemiologic criteria such as disease status at transplantation, type of donor, and conditioning regimens used. The outcome has improved only marginally over the years, with the improvement attributable mainly to better supportive care. Leukemia recurrence remains a major cause of treatment failure. Recent investigations have focused on the biology of the underlying malignancy and on transplant alloreactivity. The results of these investigations may provide a better scientific approach to indications for transplantation, do... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=3492078 Tue, 20 Apr 2010 11:21:25 +0100 3492078 http://www.medworm.com/index.php?rid=3392218&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fvp322244531r8715%2F Abstract  Monoclonal gammopathy of undetermined significance (MGUS) is characterized by the presence of a serum monoclonal (M) protein level less than 3 g/dL, less than 10% clonal plasma cells in the bone marrow, and the absence of hypercalcemia, renal insufficiency, anemia, or bone lesions attributable to a clonal plasma cell disorder. Patients may be tested for a monoclonal gammopathy by serum protein electrophoresis, immunofixation, and the free light chain (FLC) assay. The prevalence of MGUS is 3% for persons more than 50 years of age and 5% in those more than 70 years of age. The risk of progression to multiple myeloma or a related disorder is 1% per year. The size and type of M protein, the number of bone marrow plasma cells, and the results of the FLC ... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=3392218 Sat, 20 Mar 2010 11:11:54 +0100 3392218 http://www.medworm.com/index.php?rid=3375970&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fpk8762gkh21114g6%2F Abstract  The prognosis for patients with acute myelogenous leukemia (AML) is dependent on age, karyotype, and the genetics of the neoplastic cell. The molecular markers with prognostic impact include mutations in FLT3, NPM1, MLL, WT1, c-KIT, and expression levels of BAALC, NM1, ERG, and CXCR4. Gene expression profiles and microRNA expression patterns in AML may prove highly useful in defining the prognosis of AML. Cytogenetic and, increasingly, molecular findings are used in determining the best therapy for AML patients, especially the choice of whether to perform allogeneic stem cell transplantation. Content Type Journal ArticleDOI 10.1007/s11899-010-0049-7Authors Gabriela Motyckova, Dana-Farber Cancer Institute 44 Binney Street Boston MA 02115 USARichard M. Stone, Da... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=3375970 Tue, 16 Mar 2010 08:53:11 +0100 3375970 http://www.medworm.com/index.php?rid=3356155&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn047001971q4345k%2F This article reviews published data on best supportive care (BSC) in older patients with acute myeloid leukemia (AML) and proposes improvements in defining this critical aspect of treatment. A clinical challenge is to prospectively identify patients who could benefit from existing therapies and to optimize their treatment tolerance by improving BSC. Advanced age and poor performance status consistently emerge as reliable indicators of poor outcome in older AML patients and have historically been the most important variables used to stratify treatment. Performance status is notoriously difficult to assess, and a “snapshot” view at the time of initial presentation can be misleading. Comorbidity scales may be a better predictor of outcome, but studies looking at their effectiveness ... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=3356155 Wed, 10 Mar 2010 15:33:30 +0100 3356155 http://www.medworm.com/index.php?rid=3336717&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm542r2858944875x%2F Abstract  Monitoring of disease response during treatment with tyrosine kinase inhibitors of patients with chronic myelogenous leukemia dramatically changed after the introduction of real-time PCR, which allows quantification of BCR-ABL transcript levels with high sensitivity and precision. However, its role in patients who have achieved complete cytogenetic response is not entirely clear; incorrect interpretation of results could lead to unnecessary changes from an effective treatment. This review discusses the current evidence regarding the benefits, uncertainties, and potential drawbacks of molecular monitoring in patients with chronic myelogenous leukemia in chronic phase. Content Type Journal ArticleDOI 10.1007/s11899-010-0046-xAuthors Maxim Norkin, Wayne State U... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=3336717 Wed, 03 Mar 2010 08:07:57 +0100 3336717 http://www.medworm.com/index.php?rid=3328714&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw288r7u2m077n701%2F Abstract  The treatment of chronic myeloid leukemia (CML) drastically changed with the introduction of imatinib mesylate, a Bcr-Abl1 tyrosine kinase inhibitor (TKI), in 1998. By directly targeting this leukemogenic protein kinase, imatinib affords patients with CML sustained chromosomal remissions, which translate into prolonged survival. However, there has been concern over the emergence of resistance to imatinib, and some patients fail to respond or are intolerant of imatinib therapy because of untoward toxicity. This has spurred interest in developing novel TKIs to overcome the mechanisms of resistance that lead to treatment failure—most importantly, Bcr-Abl1 kinase domain mutations. Two of these second-generation TKIs, nilotinib and dasatinib, are approved worldwide f... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=3328714 Tue, 02 Mar 2010 10:07:57 +0100 3328714 http://www.medworm.com/index.php?rid=3315576&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fnt77684m28284341%2F Abstract  Allogeneic hematopoietic stem cell transplantation (HSCT) is commonly used to treat acute myeloid leukemia (AML) because it is potentially curative when other therapies have a low likelihood of success. Although most patients with newly diagnosed AML will achieve a first complete remission (CR1) with standard induction chemotherapy, obtaining a durable remission necessarily requires either further (postremission) chemotherapy or allogeneic HSCT. The decision of which of these options to choose is complex and depends on both clinical and molecular variables as well as the availability and histocompatibility of donor stem cells. Important clinical factors include the individual patient’s age, performance status, and comorbidities. Molecular and cytogenetic factors... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=3315576 Fri, 26 Feb 2010 16:44:23 +0100 3315576 http://www.medworm.com/index.php?rid=3308691&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb70148g32653826v%2F Abstract  Hematopoietic stem cell transplantation offers a curative therapy for patients with myelofibrosis. Because of toxicity, allografting following myeloablative regimens is mainly applicable to young patients. With the introduction of dose-reduced conditioning using busulfan or melphalan with fludarabine, transplantation has become tolerable also for older patients. Implementation of antithymocyte globulin in the conditioning has resulted in effective prevention of graft-versus-host disease and an increased use of alternative donors. Through the discovery of new disease-specific mutations, close monitoring of residual disease became feasible in many patients and the outcome of posttransplant strategies improved. Still challenging is the achievement of new, transplant-... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=3308691 Wed, 24 Feb 2010 06:55:54 +0100 3308691 http://www.medworm.com/index.php?rid=3308692&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F3747g056674g6544%2F Abstract  Chronic myeloid leukemia (CML) arises as a consequence of a chromosomal translocation giving rise to the Philadelphia chromosome and Bcr-Abl oncogene. CML is a clonal disease of stem cell origin and an excellent example of a malignancy in which tumor-initiating cells may hold the key to disease eradication. The known molecular basis of CML has enabled the development of Abl-specific tyrosine kinase inhibitors, such as imatinib mesylate. However, the success of tyrosine kinase inhibitors, as rationally designed first-line therapies, has been tempered by problems of disease persistence and resistance. Residual disease has been shown to be enriched within the stem cell compartment and to persist at stable levels for up to 5 years of complete cytogenetic response... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=3308692 Wed, 24 Feb 2010 06:55:53 +0100 3308692 http://www.medworm.com/index.php?rid=3190985&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc25036709p233k91%2F Abstract  Therapy for chronic lymphocytic leukemia has improved dramatically over the past 20 years. Traditional therapy with oral chlorambucil led to complete responses in less than 5% of treated patients, in marked contrast to modern regimens, which can reliably produce complete responses in over 50% of patients. This remarkable improvement is attributable to the use of purine analogue-based treatment as well as monoclonal antibodies. Novel combinations of these agents have emerged as effective new therapies for previously untreated patients. Clinical studies indicate that such combinations can induce higher response rates (including complete responses) than single-agent therapy. Those patients who achieve a complete response have superior progression-free survival c... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=3190985 Fri, 15 Jan 2010 18:05:22 +0100 3190985 http://www.medworm.com/index.php?rid=3177368&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg18qr7x885745504%2F Abstract  The clinical course of the classic myeloproliferative neoplasms (MPNs) is burdened by an increased rate of cardiovascular events, which are the major cause of mortality. Age and history of thrombosis are the criteria used to stratify patients to the most appropriate therapeutic options. However, the mechanisms ultimately responsible for the increased thrombotic tendency have not yet been elucidated; abnormalities of blood cell count, neutrophil and platelet activation, and a state of hypercoagulability can all occur. Recurrent mutations in JAK2 or MPL have been described in MPNs and serve as disease markers. There is also evidence that a JAK2V617F mutant state represents an independent factor associated with thrombosis, and abnormalities of cell function attributabl... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=3177368 Wed, 13 Jan 2010 17:55:07 +0100 3177368 http://www.medworm.com/index.php?rid=3169147&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh4552g4336264414%2F Abstract  Allogeneic hematopoietic cell transplantation (HCT) has curative potential for patients with myelodysplastic syndromes (MDS), though with considerable nonrelapse mortality and morbidity. The International Prognostic Scoring System, despite its confines, remains a widely used tool guiding treatment decisions in MDS. The two hypomethylating agents, 5-azacytidine (azacitidine) and 5-aza-2-deoxycytidine (decitabine), are both effective in high-risk MDS, but about 50% of high-risk MDS patients fail to achieve a meaningful response, and these agents offer only a modest survival benefit, with a median response duration of 13 months. The more recent proposed risk models of MDS, as well as modern transplant strategies and expanded alternative donor sources, have helpe... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=3169147 Mon, 11 Jan 2010 18:25:15 +0100 3169147 http://www.medworm.com/index.php?rid=3169148&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp1157lk67627u515%2F This article reviews our current understanding of MRD eradication and analyzes whether it is a desirable goal in the routine clinical treatment of CLL, which will optimize the management of individual patients. Content Type Journal ArticleDOI 10.1007/s11899-009-0041-2Authors Abraham M. Varghese, Bexley Wing, St James’s Institute of Oncology Department of Haematology Beckett Street Leeds LS9 7TF UKAndy C. Rawstron, Bexley Wing, St James’s Institute of Oncology Department of Haematology Beckett Street Leeds LS9 7TF UKPeter Hillmen, Bexley Wing, St James’s Institute of Oncology Department of Haematology Beckett Street Leeds LS9 7TF UK Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211 (Source: Current Hematologic Malignancy Reports) Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=3169148 Mon, 11 Jan 2010 18:25:12 +0100 3169148 http://www.medworm.com/index.php?rid=3161187&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F7000180423v46328%2F Abstract  Managing patients with myelofibrosis (MF)—either those with primary MF or those whose MF has evolved from antecedent polycythemia vera or essential thrombocythemia—presents many challenges to the hematologist. Cure is potentially achievable through allogeneic stem cell transplantation, but this therapy is either inappropriate or not feasible for most patients. MF patients suffer from a range of debilitating disease manifestations (eg, massive splenomegaly, cytopenias, constitutional symptoms, and transformation to a treatment-refractory blast phase). Currently available therapies are palliative but can be of significant value to some MF patients for anemia, splenomegaly, or sometimes both manifestations. New medical therapies for MF revolve around three main t... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=3161187 Thu, 07 Jan 2010 22:26:28 +0100 3161187 http://www.medworm.com/index.php?rid=3154684&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn612n728r2661852%2F This article reviews the clinical experience with lenalidomide, highlighting recent understanding of the dual karyotype-dependent mechanisms of action. Content Type Journal ArticleDOI 10.1007/s11899-009-0036-zAuthors Rami S. Komrokji, H. Lee Moffitt Cancer Center and Research Institute FOB-3rd Floor, 12902 Magnolia Drive Tampa FL 33612 USAJeffrey E. Lancet, H. Lee Moffitt Cancer Center and Research Institute FOB-3rd Floor, 12902 Magnolia Drive Tampa FL 33612 USAAlan F. List, H. Lee Moffitt Cancer Center and Research Institute FOB-3rd Floor, 12902 Magnolia Drive Tampa FL 33612 USA Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211 (Source: Current Hematologic Malignancy Reports) Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=3154684 Tue, 05 Jan 2010 17:03:00 +0100 3154684 http://www.medworm.com/index.php?rid=3154685&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff134532k36716j03%2F Abstract  Despite advances in treatment, chronic lymphocytic leukemia (CLL) remains incurable with standard therapies. Novel therapeutic agents are needed, particularly for patients with high-risk cytogenetic abnormalities such as del(17p13). The past year has seen several advances in this field. The immunomodulatory drug lenalidomide and the cyclin-dependent kinase inhibitor flavopiridol demonstrated clinical activity in fludarabine-refractory CLL patients with high-risk cytogenetic features and bulky lymphadenopathy, but they were associated with toxicities such as tumor flare and tumor lysis. Second-generation monoclonal anti-CD20 antibodies in clinical trials include ofatumumab, which demonstrated activity in fludarabine-refractory patients with bulky lymphadenopathy. O... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=3154685 Mon, 04 Jan 2010 18:02:16 +0100 3154685 http://www.medworm.com/index.php?rid=2853580&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm804rg3174715718%2F Abstract  Low-grade non-Hodgkin lymphomas were once considered as a heterogenous group of lymphomas characterized by an indolent clinical course. Today, low-grade non-Hodgkin lymphomas are classified as a group of 10 distinct entities, each characterized by unique clinico biologic features. Follicular lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, lymphoplasmacytic lymphoma, and marginal zone lymphoma are the most-investigated subtypes. Several studies have been performed to identify prognostic factors specific for each subtype in an effort to help clinicians in treatment decisions. The field of biologically specific associated parameters holds great potential but requires more research and work to produce translational results. Content Type Journal Ar... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=2853580 Wed, 30 Sep 2009 17:48:30 +0100 2853580 http://www.medworm.com/index.php?rid=2853581&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F5347566224154050%2F Abstract  Research on B-cell non-Hodgkin lymphoma focuses mainly on oncogenic events occurring in lymphoma cells, but recently a new component has appeared that may be crucial in lymphomagenesis: the tumor microenvironment. Indeed, compelling evidence demonstrates the key role played by nonmalignant bystander cells in the establishment and proliferation of the tumor. Among these cells, stromal cells, monocytes/macrophages, and T cells in lymphoid organs have all been described as contributing to tumor progression. Interactions linked to cell-cell intimate contacts—but also mediated through soluble mediators such as cytokines and chemokines—do form a specific network. All these interrelations directed by the tumor create a friendly environment for lymphoma cells that per... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=2853581 Wed, 30 Sep 2009 17:48:27 +0100 2853581 http://www.medworm.com/index.php?rid=2853583&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu7862417517027k1%2F This article reviews the history of DLBCL, prognostic factors, therapy, and possible future directions. Content Type Journal ArticleDOI 10.1007/s11899-009-0029-yAuthors Jason R. WestinLuis E. Fayad, University of Texas M. D. Anderson Cancer Center Department of Lymphoma/Myeloma 1515 Holcombe Boulevard, Unit #429 Houston TX 77030 USA Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211 Journal Volume Volume 4 Journal Issue Volume 4, Number 4 / October, 2009 (Source: Current Hematologic Malignancy Reports) Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=2853583 Wed, 30 Sep 2009 17:48:24 +0100 2853583 http://www.medworm.com/index.php?rid=2853582&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F45nu014874lu4324%2F This article reviews the most recent results of upfront HDT/ASCT consolidation in different subtypes of systemic PTCL. The data on allogeneic stem cell transplantation are more limited, but promising results have recently been reported in the setting of relapsed or primary refractory disease. Content Type Journal ArticleDOI 10.1007/s11899-009-0031-4Authors Francesco d’Amore, Aarhus University Hospital Department of Hematology Tage Hansens Gade 2 DK-8000 Aarhus C DenmarkEsa JantunenThomas Relander Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211 Journal Volume Volume 4 Journal Issue Volume 4, Number 4 / October, 2009 (Source: Current Hematologic Malignancy Reports) Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=2853582 Wed, 30 Sep 2009 17:48:24 +0100 2853582 http://www.medworm.com/index.php?rid=2853584&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fkr953l78821x0227%2F Abstract  Peripheral T-cell lymphomas (PTCLs) are a rare and heterogeneous group of lymphoproliferative disorders of postthymic origin. Progress in elucidating the pathobiology and appropriate therapy of these neoplasms has been slow, primarily because of their rarity, but also because until the early 1990s, they were generally grouped together and combined with B-cell lymphomas. It is now understood that most PTCLs are highly aggressive and respond poorly to standard chemo therapy, and thus they have a significantly poorer prognosis than their B-cell counterparts. In 1994, the Revised European and American Lymphoma classification provided the first uniform system to classify lymphoproliferative disorders on the basis of morphology, phenotype, genetics, and clinical feature... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=2853584 Wed, 30 Sep 2009 17:48:23 +0100 2853584 http://www.medworm.com/index.php?rid=2853585&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F36r36q0240m317p7%2F Abstract  The natural killer (NK)-cell neoplasms are rare, representing less than 1% of non-Hodgkin lymphoma, except in Asia and Latin America, where they represent 3% to 6%. NK-cell neoplasms include immature acute leukemias; a blastic NK-cell lymphoma, which is obsolete because of its plasmacytoid dendritic-cell origin; and mature NK neoplasms, comprising extranodal NK/T-cell lymphoma (ENKL), nasal-type; aggressive NK-cell leukemia; and chronic NK-cell lymphoproliferative disorders, which are often reactive. Epstein-Barr virus is usually detected in tumor cells of ENKL and aggressive NK-cell leukemia. The latter two mature NK neoplasms are relatively chemoresistant because of the frequent expression of P-glycoprotein. Early radiation is advocated for localized nasal ENKL.... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=2853585 Wed, 30 Sep 2009 17:48:20 +0100 2853585 http://www.medworm.com/index.php?rid=2853586&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F2622335234j68m50%2F Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11899-009-0033-2Authors Peter McLaughlin, The University of Texas M. D. Anderson Cancer Center Department of Lymphoma/Myeloma Houston USA Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211 Journal Volume Volume 4 Journal Issue Volume 4, Number 4 / October, 2009 (Source: Current Hematologic Malignancy Reports) Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=2853586 Wed, 30 Sep 2009 17:48:17 +0100 2853586 http://www.medworm.com/index.php?rid=2853588&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh7332jk771761203%2F Abstract  Follicular lymphoma is one of the most immuneresponsive cancers. The clonal tumor immunoglobulin expressed on the surface of malignant B cells, termed idiotype, has been used as a tumor-specific antigen in therapeutic vaccination strategies for follicular lymphoma and other B-cell malignancies. A number of phase 1 and phase 2 clinical trials have established the safety and immunogenicity of idiotype vaccine in follicular lymphoma. Three randomized, double-blind, controlled phase 3 clinical trials have recently been completed to definitively evaluate the clinical benefit of idiotype vaccine in follicular lymphoma. This review focuses on the results of these idiotype vaccine trials and discusses poten tial strategies to enhance the efficacy of vaccines in the future.... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=2853588 Wed, 30 Sep 2009 17:48:16 +0100 2853588 http://www.medworm.com/index.php?rid=2853587&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh7tj414426136m64%2F Abstract  Mantle cell lymphoma (MCL) is a unique lymphoma subtype comprising 6% to 8% of new lymphoma diagnoses. It is generally considered to be incurable with standard lymphoma therapies. The median overall survival (OS) is often reported to be 3 to 4 years, but more recent data suggest that the median OS may be longer than 5 years. There is considerable heterogeneity in MCL, with some patients succumbing to their disease in less than a year and others surviving for more than 10 years. The biology of MCL is reasonably well understood, and targeted therapies based on this knowledge are in development. Clinical trials incorporating new agents into standard therapies are under way. The optimal frontline treatment strategy is not defined and is a source of controversy. Intens... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=2853587 Wed, 30 Sep 2009 17:48:16 +0100 2853587 http://www.medworm.com/index.php?rid=2853589&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F148462440n7r8qh2%2F Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11899-009-0034-1Authors Nicole Lamanna, Leukemia Service at Memorial Sloan-Kettering Cancer Center New York NY USAMark A. Weiss, Leukemia Service at Memorial Sloan-Kettering Cancer Center New York NY USA Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211 Journal Volume Volume 4 Journal Issue Volume 4, Number 4 / October, 2009 (Source: Current Hematologic Malignancy Reports) Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=2853589 Wed, 30 Sep 2009 17:48:12 +0100 2853589 http://www.medworm.com/index.php?rid=2565089&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh542t178r86n7473%2F Abstract  Limited-stage Hodgkin lymphoma remains a challenging problem for pediatric oncologists. Published and investigative treatment regimens represent varied approaches to balance the excellent overall and event-free survival with the substantial potential for long-term sequelae of effective treatment modalities. Regimens incorporating low-dose radiation to smaller fields and chemotherapy that limits cumulative exposure to the agents most closely associated with long-term complications have been shown to be effective for most patients. Investigative approaches to optimize overall therapy focus on identifying which patients require more or less therapy. A recent example is the use of response-based therapy as a means of limiting or omitting radiation for those with an ea... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=2565089 Tue, 30 Jun 2009 15:57:44 +0100 2565089 http://www.medworm.com/index.php?rid=2565092&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F0572206334u41643%2F Abstract  The outcome of salvage therapy for relapsed acute lymphoblastic leukemia (ALL) remains poor. Salvage therapy mimics regimens with activity in newly diagnosed ALL. Novel strategies under investigation as monotherapy or in combination with chemotherapy improve the treatment of relapsed disease. For some ALL subsets, specific therapies are indicated. The addition of targeted therapy in Philadelphia chromo some-positive ALL has improved responses in relapsed patients without resistance to available tyrosine kinase inhibitors. Nelarabine demonstrates activity as monotherapy in T-cell ALL and is approved by the US Food and Drug Administration. Clofarabine, a second-generation purine analogue approved in pediatric leukemia, has shown activity in adult acute leukemias inc... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=2565092 Tue, 30 Jun 2009 15:57:39 +0100 2565092 http://www.medworm.com/index.php?rid=2565091&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F0814782521286112%2F Abstract  Compared with acute lymphoblastic leukemia (ALL) in older children, ALL in infants has a dismal outcome because rearrangements of the mixed-lineage leukemia (MLL) gene occur in about 80% of these patients, leading to an aggressive type of leukemia. With most recent therapies, about 50% long-term event-free survival is achieved, but early bone marrow relapse remains a major problem. Early intensification of chemotherapy and new innovative therapies are necessary to improve outcome. Bone marrow transplantation should be limited to a small subset of well-recognized ALL patients with a very poor prognosis. New genetic and epigenetic insights into the biology of MLL-rearranged ALL suggest new possibilities for therapies. Content Type Journal ArticleDOI 10.1007/s11899... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=2565091 Tue, 30 Jun 2009 15:57:39 +0100 2565091 http://www.medworm.com/index.php?rid=2565090&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F04u62nj808m4u113%2F Abstract  Over half a century, radiation therapy (RT) for Hodgkin lymphoma has been transformed from a radical, extensive, high-dose therapy (which alone cured most patients) into an essential component of a comprehensive combined-modality program. RT is now used in a “mini” version that encompasses only the clinically involved sites following chemotherapy and is administered in a markedly reduced dose. This change has considerably reduced the long-term complications that were associated with the now-outdated radical RT approach. The use of RT also allows a shorter and safer course of chemotherapy. The combination of reduced chemotherapy followed by mini-RT has produced disease control and even overall results that are significantly superior to those achieved with chemo... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=2565090 Tue, 30 Jun 2009 15:57:39 +0100 2565090 http://www.medworm.com/index.php?rid=2565093&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk3295r0271881552%2F Abstract  Despite great progress in the curative treatment of leukemia in pediatrics, current therapies are associated with multiple toxicities and the prognosis after relapse is guarded. Novel approaches are needed to overcome resistance to standard therapy and decrease adverse effects. The efficacy of allogeneic stem cell transplantation and the demonstration of a graft-versus-leukemia effect suggest that immune-based therapies can be effective in the treatment of childhood leukemia. Efforts to apply new immunotherapy approaches to the treatment of leukemia in pediatrics have recently begun. The optimal reagents, methods, and regimens have yet to be fully defined. Ongoing clinical trials offer promise in that regard. Content Type Journal ArticleDOI 10.1007/s11899-009-00... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=2565093 Tue, 30 Jun 2009 15:56:35 +0100 2565093 http://www.medworm.com/index.php?rid=2565095&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fj1105303w721gh11%2F Abstract  This is an exciting time in drug development for acute lymphoblastic leukemia (ALL). A confluence of trends makes it likely that highly effective new agents for ALL will be identified in the coming decade. One contributory factor is the development of more representative preclinical models of ALL for testing and prioritizing novel agents. Another important trend in ALL drug development is the increasing understanding at the molecular level of the genomic changes that occur in B-precursor and T-cell ALL. A final important trend is the increasing availability of new agents against relevant molecular targets. Molecularly targeted agents of interest discussed in this review include novel antibody-based drugs targeted against leukemia surface antigens, proteasome inhib... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=2565095 Tue, 30 Jun 2009 15:56:34 +0100 2565095 http://www.medworm.com/index.php?rid=2565094&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft02nl0864833757n%2F Abstract  Allogeneic hematopoietic stem cell transplantation (alloHCT) is the single most potent treatment modality to prevent relapse in adults with acute lymphocytic leukemia, but its optimal use and timing remains a matter of intense debate and research. There is general agreement that patients with clinical features of high risk for relapse should undergo alloHCT in first complete remission. However, newer studies suggest that even patients without these risk factors may benefit. Monitoring of minimal residual disease may improve risk stratification and may complement or replace conventional risk features. Prognosis in relapsed and refractory patients is dismal, and alloHCT should be performed as soon as possible. AlloHCT also offers the only reasonable chance for cure ... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=2565094 Tue, 30 Jun 2009 15:56:34 +0100 2565094 http://www.medworm.com/index.php?rid=2565097&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh4462462n17g7xh1%2F This article reviews the different aspects of HL and B-cell non-Hodgkin lymphoma (B-NHL), concluding that—despite the same cell of origin—fundamental differences exist in morphology, cellular composition, immunophenotype, activation or inhibition of transcription factors, epigenetics, and clinical behavior. These findings lead us to conclude that HL and B-NHLs should stay as two separate categories. Content Type Journal ArticleDOI 10.1007/s11899-009-0018-1Authors Harald Stein, Charité University of Medicine Pathology Institute, Campus Benjamin Franklin Hindenburgdamm 30 12200 Berlin GermanyRoshanak Bob Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211 Journal Volume Volume 4 Journal Issue Volume 4, Number 3 / July, 2009 (Sou... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=2565097 Tue, 30 Jun 2009 15:56:32 +0100 2565097 http://www.medworm.com/index.php?rid=2565096&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fht6275547u3j510l%2F Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11899-009-0016-3Authors James O. Armitage, University of Nebraska Medical Center Section of Oncology and Hematology Omaha USA Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211 Journal Volume Volume 4 Journal Issue Volume 4, Number 3 / July, 2009 (Source: Current Hematologic Malignancy Reports) Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=2565096 Tue, 30 Jun 2009 15:56:32 +0100 2565096 http://www.medworm.com/index.php?rid=2288593&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc70l33011116kw46%2F Abstract  Multiple myeloma (MM) is the second most common hematologic malignancy and the most common malignancy to involve bone. More than 85% of patients with MM have bone involvement, which can be devastating. Bisphosphonate therapy is the mainstay of treatment for MM bone disease; it has decreased the frequency of skeletal events in MM and delayed their development. Further, the toxicity of these drugs is low and generally manageable. Whether bisphosphonates have any antitumor effects in MM patients (in contrast to what has been reported in preclinical models) is unclear and requires further study. Although bisphosphonates have been extremely effective for treating MM bone disease, they do not completely inhibit the development of skeletal events, but only decrease them ... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=2288593 Sun, 22 Mar 2009 06:08:33 +0100 2288593 http://www.medworm.com/index.php?rid=2288594&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fj70537n80n4p3546%2F This article outlines some of the data underpinning the use of bortezomib, thalidomide, lenalidomide, or combinations of these agents in the setting of relapsed myeloma, as well as a number of potential future agents or combinations that may improve outcomes for patients with relapsed and refractory disease. Content Type Journal ArticleDOI 10.1007/s11899-009-0014-5Authors Jonathan KaufmanCharise GleasonSagar Lonial, Emory University Winship Cancer Institute 1365 Clifton Road, Building C, Room 4004 Atlanta GA 30322 USA Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211 Journal Volume Volume 4 Journal Issue Volume 4, Number 2 / April, 2009 (Source: Current Hematologic Malignancy Reports) Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=2288594 Sun, 22 Mar 2009 06:08:31 +0100 2288594 http://www.medworm.com/index.php?rid=3098198&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fhvulp85816183375%2F Abstract  c-Kit is a receptor tyrosine kinase (RTK) with a pivotal role in melanogenesis, gametogenesis, and hematopoiesis. Aberrantly activated RTK and related downstream signaling partners were identified as key elements in the molecular pathogenesis of several malignancies. This finding culminated in a two-class model integrating constitutive activating and maturation arrest-inducing mutations as key elements for the pathogenesis of acute myelogenous leukemia (AML). c-Kit is expressed by myeloblasts in about 60% to 80% of patients, and the most frequently observed activating RTK mutations in AML (next to FLT3) are mutations or internal tandem duplications in c-Kit, with an overall incidence of 17%. The identification of small-molecule tyrosine kinase inhibitors capable of... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=3098198 Sun, 22 Mar 2009 06:08:30 +0100 3098198 http://www.medworm.com/index.php?rid=2288599&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F97550007u2r50893%2F Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11899-009-0008-3Authors Hien K. DuongMatt Kalaycio Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211 Journal Volume Volume 4 Journal Issue Volume 4, Number 2 / April, 2009 (Source: Current Hematologic Malignancy Reports) Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=2288599 Sun, 22 Mar 2009 06:08:30 +0100 2288599 http://www.medworm.com/index.php?rid=2288598&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fhvulp85816183375%2F Abstract  c-Kit is a receptor tyrosine kinase (RTK) with a pivotal role in melanogenesis, gametogenesis, and hematopoiesis. Aberrantly activated RTK and related downstream signaling partners were identified as key elements in the molecular pathogenesis of several malignancies. This finding culminated in a two-class model integrating constitutive activating and maturation arrest-inducing mutations as key elements for the pathogenesis of acute myelogenous leukemia (AML). c-Kit is expressed by myeloblasts in about 60% to 80% of patients, and the most frequently observed activating RTK mutations in AML (next to FLT3) are mutations or internal tandem duplications in c-Kit, with an overall incidence of 17%. The identification of small-molecule tyrosine kinase inhibitors capable of... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=2288598 Sun, 22 Mar 2009 06:08:30 +0100 2288598 http://www.medworm.com/index.php?rid=2288597&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh3660t5nn4860201%2F Abstract  Tyrosine kinase inhibitor (TKI) therapy has significantly changed the treatment paradigm for patients with chronic myeloid leukemia (CML). The firs-tgeneration inhibitor, imatinib, has demonstrated remarkable efficacy in most chronic-phase patients. Disease progression remains a significant risk for the first 2 to 3 years of TKI therapy, but the risk falls significantly thereafter. Early recognition of each individual’s risk of progression may facilitate a customized approach to TKI therapy. Using such an approach, drug selection and treatment intensity would be adjusted on the basis of each patient’s disease profile. Currently available prognostic indicators have limited value in the setting of the potent kinase inhibition afforded by TKIs. Furthermore, these... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=2288597 Sun, 22 Mar 2009 06:08:30 +0100 2288597 http://www.medworm.com/index.php?rid=2288596&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F2k8n5p502q593t45%2F Abstract  No therapy is uniformly effective in the management of immunoglobulin light chain amyloidosis (AL amyloidosis). Despite the common generalization, therapy is highly effective. Options available to patients with AL amyloidosis include high-dose therapy, but this is applicable to only about one fourth of patients. Therapies shown to be effective are based on alkylators, dexamethasone, or combinations of an alkylator and steroids. In the past 5 years, novel agents previously shown to be effective in multiple myeloma (eg, thalidomide, lenalidomide, and bortezomib) have been shown to have efficacy in the management of AL amyloidosis. Predictors of outcome include the serum brain natriuretic peptide, the number of organs involved, and the severity of cardiac involvement... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=2288596 Sun, 22 Mar 2009 06:08:30 +0100 2288596 http://www.medworm.com/index.php?rid=2288595&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F2803710624751464%2F This article reviews recent developments in the biology and treatment of CML, specifically focusing on CML stem cells. Significant progress continues to be made in our understanding of CML stem cell biology, which has wider implications within the cancer stem cell field. We are also beginning to see the identification of novel therapies that specifically target the CML stem cell. These are exciting times in the quest to cure CML. Content Type Journal ArticleDOI 10.1007/s11899-009-0010-9Authors Mhairi Copland, Gartnavel General Hospital Leukaemia Research Centre 1053 Great Western Road Glasgow G12 0YN UK Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211 Journal Volume Volume 4 Journal Issue Volume 4, Number 2 / April, 2009 (Sourc... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=2288595 Sun, 22 Mar 2009 06:08:30 +0100 2288595 http://www.medworm.com/index.php?rid=2288600&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F871283034127q48n%2F This article reviews recent studies that were focused on the alterations of microRNA expression in AML and their diagnostic and prognostic significance. Content Type Journal ArticleDOI 10.1007/s11899-009-0012-7Authors Guido Marcucci, The Ohio State University The Comprehensive Cancer Center A433B Starling-Loving Hall, 320 West 10th Avenue Columbus OH 43210 USAMichael D. RadmacherKrzysztof MrózekClara D. Bloomfield Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211 Journal Volume Volume 4 Journal Issue Volume 4, Number 2 / April, 2009 (Source: Current Hematologic Malignancy Reports) Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=2288600 Sun, 22 Mar 2009 06:08:27 +0100 2288600 http://www.medworm.com/index.php?rid=2065179&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fd5480328142305x3%2F Abstract  Myelodysplastic syndromes (MDS) are a diverse group of disorders characterized by disorderly and ineffective hematopoiesis. Patients suffer morbidity from associated cytopenias that result in an increased risk of infection, transfusion-dependent anemia, and bleeding. Despite the variable risk of transformation to acute leukemia, the majority of deaths are due to bone marrow failure. No truly effective treatment exists for MDS, and therapy usually focuses on reducing or preventing complications of the disease. Identification of potential cellular and molecular targets, such as epigenetic modification, has led to novel therapeutic approaches in recent years. An increasing number of diagnostic markers, prognostic parameters, and therapeutic strategies are available a... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=2065179 Wed, 24 Dec 2008 07:41:14 +0100 2065179 http://www.medworm.com/index.php?rid=2065183&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb78583005703m5h5%2F This article describes various methods of assessing minimal residual disease and presents data demonstrating that new therapeutic approaches can eliminate residual malignant cells at the highest levels of sensitivity currently available. Although initial evidence suggests that the use of alemtuzumab induces a survival benefit when used in the consolidation setting, important safety issues remain to be resolved before this approach can be introduced in routine practice. Content Type Journal ArticleDOI 10.1007/s11899-009-0006-5Authors Thomas Elter, University of Cologne Department I of Internal Medicine Kerpener Strasse 62 50937 Cologne GermanyBarbara F. EichhorstClemens-Martin Wendtner Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211 ... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=2065183 Wed, 24 Dec 2008 07:41:13 +0100 2065183 http://www.medworm.com/index.php?rid=2065182&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu8614766345l2n64%2F Abstract  Polycythemia vera is a chronic myeloproliferative disorder affecting people in the sixth decade of life. The disease is considered long-lasting; median survival exceeds 18 years. As thrombosis is the main complication during follow-up, scoring systems have focused on the risk of thrombosis. Age over 60 years and prior thrombosis are considered the standard risk factors for thrombosis and represent the state of the art for risk stratification in decision making regarding treatment. However, new disease-based risk factors—leukocytosis and the JAK2V617F mutation burden—seem to be emerging as indicators of prognosis in polycythemia vera. Leukocytosis, as a marker of disease proliferation, seems to have an impact on thrombosis, post-polycythemia vera myelofibrosis, ... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=2065182 Wed, 24 Dec 2008 07:41:13 +0100 2065182 http://www.medworm.com/index.php?rid=2065181&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc847522268jk27uu%2F Abstract  Several international working groups cooperated to propose new diagnostic guidelines for polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) to the steering committee of the World Health Organization. Because JAK2 mutation status presents a decisive diagnostic test in PV, this feature was introduced as a major criterion. Minor criteria, such as characteristic bone marrow morphology, low erythropoietin level, and erythroid colony formation, were kept as supporting parameters. In PMF, major diagnostic criteria were established by histologic features independent of the presence of relevant fibrosis or myelofibrosis with myeloid metaplasia. JAK2 mutation status was restricted to positive findings to exclude reactive myelofibrosis. A ... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=2065181 Wed, 24 Dec 2008 07:41:13 +0100 2065181 http://www.medworm.com/index.php?rid=2065180&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv840416643v73792%2F Abstract  The majority of patients with myelodysplastic syndromes (MDS) are older, and the incidence of these diseases is rising as the population ages. Clinicians are often uncertain about how to identify patients who may benefit from specific treatment strategies. The International Prognostic Scoring System is a widely used tool to assess risk of transformation to leukemia and guide treatment decisions, but it fails to take into account many aspects of treating elderly patients, including comorbid illness, secondary causes of MDS, prior therapy for MDS, and other age-related health, functional, cognitive, and social problems that affect outcome. Patients with lowrisk disease traditionally have been given supportive care, but evidence is increasing that treatment with lena... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=2065180 Wed, 24 Dec 2008 07:41:13 +0100 2065180 http://www.medworm.com/index.php?rid=3098199&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft27733q2873572l1%2F This article reviews its impact upon our knowledge regarding essential thrombocythemia. The discovery of JAK2V617F has led to the proposal that essential thrombocythemia, polycythemia vera, and primary myelofibrosis be discarded as separate diagnoses, and the rationale for this change is discussed. Simplified diagnostic criteria based upon testing for JAK2V617F are proposed. Interesting data are emerging regarding disease progression and risk of complications, specifically thrombosis, pregnancy loss, and perhaps progression to myelofibrosis. The JAK2V617F allele burden is emerging as a potentially important risk factor, although its measurement is not yet standardized. It also may serve as a tool for monitoring the effects of emerging novel therapies, which hold the potential to revolu... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=3098199 Wed, 24 Dec 2008 07:41:12 +0100 3098199 http://www.medworm.com/index.php?rid=2065185&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa66h446m31351549%2F Abstract  Autoimmune hemolytic anemia (AIHA) and immune thrombocytopenic purpura (ITP) are recognized complications of chronic lymphocytic leukemia (CLL) that can be life-threatening if not managed appropriately. Conventional therapies for these autoimmune disorders, such as corticosteroids, splenectomy, and immunosuppressive agents, may not induce complete resolution in all patients, and relapses are common. In recent years, monoclonal antibodies such as alemtuzumab and rituximab, already used successfully for the management of lymphoproliferative disorders, have been shown to be effective in the treatment of a range of autoimmune disorders. The potent antitumor activity of alemtuzumab, in combination with its profound immunosuppressive activity, prompted investigation of ... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=2065185 Wed, 24 Dec 2008 07:41:12 +0100 2065185 http://www.medworm.com/index.php?rid=2065184&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft27733q2873572l1%2F This article reviews its impact upon our knowledge regarding essential thrombocythemia. The discovery of JAK2V617F has led to the proposal that essential thrombocythemia, polycythemia vera, and primary myelofibrosis be discarded as separate diagnoses, and the rationale for this change is discussed. Simplified diagnostic criteria based upon testing for JAK2V617F are proposed. Interesting data are emerging regarding disease progression and risk of complications, specifically thrombosis, pregnancy loss, and perhaps progression to myelofibrosis. The JAK2V617F allele burden is emerging as a potentially important risk factor, although its measurement is not yet standardized. It also may serve as a tool for monitoring the effects of emerging novel therapies, which hold the potential to revolu... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=2065184 Wed, 24 Dec 2008 07:41:12 +0100 2065184 http://www.medworm.com/index.php?rid=1886245&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fy165t3803842350p%2F Abstract  Follicular lymphoma (FL) is a neoplasm derived from follicular germinal center cells. Like the normal components of this lymphoid structure, FL cells interact with various immune cells, such as the follicular helper T cells, suppressor regulatory T cells, dendritic cells, and histiocytes, that define the tumor microenvironment. Gene expression studies have shown that the nature of the tumor microenvironment predicts survival in patients with FL and may influence the response to immunotherapy and risk of transformation. The immune system may either promote or constrain tumor cell development, depending on the relative distribution and activation status of various cell subpopulations. The prognostic value of germline genetic variants of some immune genes suggests th... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=1886245 Thu, 16 Oct 2008 09:59:22 +0100 1886245 http://www.medworm.com/index.php?rid=1886244&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fy504534217713138%2F Abstract  The treatment of non-Hodgkin lymphoma (NHL) has changed dramatically since the introduction of rituximab, a monoclonal antibody that binds to the B-cell transmembrane protein CD20 and causes lysis of the lymphoma cells. Since then, a number of additional antibodies have been tested against other B-cell targets, resulting in variable efficacies. The goal of these newer agents is to achieve similar or better response rates as seen with rituximab and perhaps demonstrate activity in rituximab-refractory disease. Several of the antibodies have been investigated in combination with each other as well as with conventional chemotherapeutic regimens. Approval of such antibodies by regulatory committees and their eventual integration into clinical practice will likely depen... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=1886244 Thu, 16 Oct 2008 09:59:22 +0100 1886244 http://www.medworm.com/index.php?rid=1886243&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg781155w6704k4t3%2F Content Type Journal ArticleDOI 10.1007/s11899-008-0025-7 Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211 Journal Volume Volume 3 Journal Issue Volume 3, Number 4 / October, 2008 (Source: Current Hematologic Malignancy Reports) Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=1886243 Thu, 16 Oct 2008 09:59:22 +0100 1886243 http://www.medworm.com/index.php?rid=1886249&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm88w378216472175%2F This article reviews current knowledge relating to inherited susceptibility to CLL and strategies that are being used to identify disease-causing mutations. Content Type Journal ArticleDOI 10.1007/s11899-008-0031-9Authors Richard S. Houlston, Institute of Cancer Research Section of Cancer Genetics 15 Cotswold Road Sutton Surrey SM2 5NG UKDaniel Catovsky Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211 Journal Volume Volume 3 Journal Issue Volume 3, Number 4 / October, 2008 (Source: Current Hematologic Malignancy Reports) Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=1886249 Thu, 16 Oct 2008 09:59:21 +0100 1886249 http://www.medworm.com/index.php?rid=1886248&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F65760523t77h9285%2F Abstract  Peripheral T-cell lymphomas (PTCLs) are a rare and heterogeneous group of disorders associated with a very poor prognosis. Historically, treatment protocols have been largely based on regimens used to treat aggressive B-cell lymphomas; unfortunately, the efficacy of these regimens has been suboptimal, with most patients experiencing relapse after initial therapy. An improved understanding of the molecular biology, pathogenesis, and progression of these disorders has led to the development of a variety of novel targeted agents that may improve outcomes in patients with PTCLs. The purpose of this review is to focus on these novel agents and the various treatment approaches that are currently being evaluated in PTCLs. Content Type Journal ArticleDOI 10.1007/s11899-... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=1886248 Thu, 16 Oct 2008 09:59:21 +0100 1886248 http://www.medworm.com/index.php?rid=1886247&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn21544h631204662%2F Abstract  Mantle cell lymphoma (MCL) is a therapeutic challenge because of its lower cure rate when compared with other lymphomas such as diffuse large cell lymphoma. The current emphasis in the treatment of newly diagnosed MCL has been on intensifying chemotherapy, but there is no consensus on the need to consolidate with autologous stem cell transplantation. These approaches, however, have not resulted in a cure. Newer strategies include the use of models to aid in tailoring therapy. Likewise, autologous stem cell consolidation does not cure relapsed disease. Because of its known graft-versus-lymphoma effect, allogeneic stem cell transplantation offers a potentially curative option for relapsed MCL. New insights into resistance pathways and new drugs created to inhibit th... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=1886247 Thu, 16 Oct 2008 09:59:21 +0100 1886247 http://www.medworm.com/index.php?rid=1886246&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff577k357801p1v53%2F Abstract  Lymphoma comprises a complex set of diseases, including Hodgkin and non-Hodgkin subtypes. An expected goal of management is chronic disease control over decades in most patients with indolent subtypes, and cure is a realistic target for aggressive histologies, including Hodgkin lymphoma. Making methods available to better assess prognosis and to more specifically tailor therapy toward individual subtypes is a priority. Positron emission tomography using the tracer 18fluoro-2-deoxyglucose (FDG-PET) has become a valuable tool in the care of patients with lymphoma; it contributes information on staging and response assessment that has the potential to affect and improve patient care. This imaging modality is also being explored as an early response assessor, potential... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=1886246 Thu, 16 Oct 2008 09:59:21 +0100 1886246 http://www.medworm.com/index.php?rid=1870523&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fjln8127uu6x41t2p%2F Abstract  Acute lymphoblastic leukemia (ALL) has a bimodal age distribution with a peak occurring during early childhood and a second peak after age 45. Although all patients are treated with similar intensive chemotherapy regimens, good outcomes have occurred more frequently in children than adults. Most children with ALL have been able to achieve a complete remission (CR) with an induction rate of about 98% and a 5-year estimated event-free survival rate (EFS) rate of about 80%. Unfortunately, the results for adults are less encouraging. Current adult treatment regimens result in CR rates approaching 80%, with EFS at 5 years of only 30% to 40%. Regardless of age, patients with relapsed or refractory ALL have extremely poor outcomes, because CR rates are low and seldom dur... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=1870523 Fri, 10 Oct 2008 08:18:33 +0100 1870523 http://www.medworm.com/index.php?rid=1870527&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F8mhg91l664204u12%2F This article discusses the methodologies available for productive MRD testing and the clinical significance of the results. Content Type Journal ArticleDOI 10.1007/s11899-008-0022-xAuthors Dario Campana, St. Jude Children’s Research Hospital Department of Oncology 332 North Lauderdale Memphis TN 38105 USA Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211 Journal Volume Volume 3 Journal Issue Volume 3, Number 3 / July, 2008 (Source: Current Hematologic Malignancy Reports) Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=1870527 Fri, 10 Oct 2008 08:18:32 +0100 1870527 http://www.medworm.com/index.php?rid=1870526&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fq01m3816405m5351%2F Abstract  Age at diagnosis remains one of the strongest prognostic factors in acute lymphoblastic leukemia (ALL), with older patients having inferior outcomes compared with younger patients. Adolescents and young adults (AYAs) with ALL (age 15–30 years) represent a patient subgroup with distinctive biology whose optimal therapy has yet to be determined. Compared with younger children with ALL, AYAs are more likely to present with unfavorable presenting characteristics (such as high presenting leukocyte counts, T-cell phenotype, and the Philadelphia chromosome). Additionally, AYAs with ALL experience more regimen-related toxicity than younger patients. Recent retrospective studies suggest that patients age 15 to 21 years treated on pediatric ALL regimens have better outcom... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=1870526 Fri, 10 Oct 2008 08:18:32 +0100 1870526 http://www.medworm.com/index.php?rid=1870525&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F96356267204nl254%2F Abstract  Long-term survivors of Hodgkin lymphoma face a number of late effects that can significantly affect the length and quality of their life. These include increased risk of second malignancy, cardiovascular disease, pulmonary dysfunction, infections, and endocrinopathy. Of these late effects, second malignancies and cardiac disease are the two leading contributors to the excess mortality seen in long-term Hodgkin lymphoma survivors. An improved understanding of the range of late complications after Hodgkin lymphoma therapy and the identification of treatment-related and patient-related risk factors can guide the development of screening and prevention programs for long-term survivors who have completed treatment. In addition, increasing recognition of late complicati... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=1870525 Fri, 10 Oct 2008 08:18:32 +0100 1870525 http://www.medworm.com/index.php?rid=1870524&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F27253g372lp823p1%2F Abstract  Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare subtype of Hodgkin lymphoma that differs from classic Hodgkin lymphoma (cHL) with respect to histologic and clinical presentation. Because the prognosis of NLPHL in early unfavorable and advanced stages is similar to that of cHL, treatment is similar. In contrast, early favorable-stage NLPHL has a better prognosis than cHL. Thus, NLPHL in early favorable stages might be treated with reduced-intensity programs without compromising cure rates. Because involved-field radiotherapy alone seems to be as effective as extended-field radiotherapy or combined modalities, it has been adopted by the German Hodgkin Study Group and the European Organisation for Research and Treatment of Cancer as the treatment of... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=1870524 Fri, 10 Oct 2008 08:18:32 +0100 1870524 http://www.medworm.com/index.php?rid=1870530&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F75541210546n6888%2F Abstract  Non-Hodgkin lymphoma (NHL) accounts for 7% of cancer in children and adolescents in the United States, or approximately 1000 cases annually. NHL in the pediatric population differs from that observed in adult patients with respect to staging systems, histologic subtypes of disease, treatment, and outcomes. Although more than 90% of pediatric NHL is of high-grade histology, more than 80% of patients achieve long-term event-free survival with modern therapy. This review focuses on current treatments for pediatric NHL and some of the differences between NHL observed in pediatric and adult patients. Content Type Journal ArticleDOI 10.1007/s11899-008-0024-8Authors Thomas G. Gross, Division of Hematology/Oncology/BMT, Children’s Hospital Department of Pediatrics, T... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=1870530 Fri, 10 Oct 2008 08:18:31 +0100 1870530 http://www.medworm.com/index.php?rid=1870529&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F77m342081l575463%2F Content Type Journal ArticleDOI 10.1007/s11899-008-0017-7 Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211 Journal Volume Volume 3 Journal Issue Volume 3, Number 3 / July, 2008 (Source: Current Hematologic Malignancy Reports) Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=1870529 Fri, 10 Oct 2008 08:18:31 +0100 1870529 http://www.medworm.com/index.php?rid=1870528&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fym512m6076236m12%2F Abstract  Acute lymphoblastic leukemia affects infants, children, adolescents, and adults. Although most children have a high likelihood of cure, outcomes in adults have much room for improvement. In between lies the adolescent and young adult population, not only in terms of age but also in clinical success rates. This review describes biology, prognostic factors, and treatment approaches in adolescents and young adults with acute lymphoblastic leukemia. Assessing the outcomes in adult and pediatric clinical trials that enroll adolescents and young adults can be especially useful in determining how best to treat these patients. Current new treatment strategies are also discussed. Content Type Journal ArticleDOI 10.1007/s11899-008-0021-yAuthors Ryan MattisonWendy Stock,... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=1870528 Fri, 10 Oct 2008 08:18:31 +0100 1870528 http://www.medworm.com/index.php?rid=1411723&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F5m12l42171q38667%2F Content Type Journal ArticleDOI 10.1007/s11899-008-0010-1 Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211 Journal Volume Volume 3 Journal Issue Volume 3, Number 2 / April, 2008 (Source: Current Hematologic Malignancy Reports) Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=1411723 Tue, 29 Apr 2008 06:08:24 +0100 1411723 http://www.medworm.com/index.php?rid=1411724&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv32353hn8468262k%2F Abstract  Imatinib has revolutionized the treatment of chronic myelogenous leukemia (CML). Given the high rates of complete cytogenetic remission achieved with imatinib therapy, molecular monitoring of BCR-ABL transcript levels by real-time quantitative polymerase chain reaction has become the method of choice to assess the amount of residual disease below the cytogenetic threshold. BCR-ABL transcript levels measured at specific times during therapy may predict durable cytogenetic remission and prolonged progression-free survival or, on the contrary, failure and suboptimal response, thus directing clinical decisions. Recently, recommendations have been established for harmonizing the methodologies used to measure BCR-ABL transcripts in patients with CML, allowing results to... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=1411724 Tue, 29 Apr 2008 06:08:22 +0100 1411724 http://www.medworm.com/index.php?rid=1411725&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl3742930384t1618%2F Abstract  Acute myelogenous leukemia (AML) results from a differentiation block of hematopoietic progenitor cells along with uncontrolled proliferation. The cytogenetic abnormality at initial diagnosis is the single most important prognostic factor classifying AML patients into three prognostic categories: favorable, intermediate, and poor risk. Currently, favorable-risk AML patients are usually treated with contemporary chemotherapy, and poor-risk AML patients receive allogeneic stem cell transplantation if suitable stem cell donors exist. The approximately 40% of AML patients without identifiable cytogenetic abnormalities (NC AML) are classified as intermediate risk. The optimal therapeutic strategies for these patients are largely unclear. Emerging data recently suggeste... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=1411725 Tue, 29 Apr 2008 06:08:21 +0100 1411725 http://www.medworm.com/index.php?rid=1411728&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu52112523624v358%2F This article reviews the results of important trials in which TSC was used as an induction regimen in de novo, relapsed, or refractory acute myelogenous leukemia or as postremission therapy. Content Type Journal ArticleDOI 10.1007/s11899-008-0014-xAuthors Xavier Thomas, Hôpital Edouard Herriot Service d’Hématologie 69437 Lyon Cedex 03 France Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211 Journal Volume Volume 3 Journal Issue Volume 3, Number 2 / April, 2008 (Source: Current Hematologic Malignancy Reports) Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=1411728 Tue, 29 Apr 2008 06:08:20 +0100 1411728 http://www.medworm.com/index.php?rid=1411727&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F440qp04275876323%2F Abstract  Multiple myeloma (MM) is the second most common oncohematologic disease. Most patients are older than 65 years at diagnosis, and different therapeutic options are available depending on the age of the patient. For those younger than 65 years, autologous stem cell transplantation is the standard of care, whereas in older patients the better choice is conventional chemotherapy. The introduction of thalidomide, bortezomib, and lenalidomide, which target MM cells and the bone marrow microenvironment, has changed the therapeutic options in newly diagnosed patients with MM. Content Type Journal ArticleDOI 10.1007/s11899-008-0016-8Authors Antonio Palumbo, Azienda Ospedaliera S. Giovanni Battista Divisione di Ematologia dell’Università di Torino Via Genova 3 10126 T... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=1411727 Tue, 29 Apr 2008 06:08:20 +0100 1411727 http://www.medworm.com/index.php?rid=1411726&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc351430468851k67%2F Abstract  The introduction of imatinib represented a breakthrough in the treatment of chronic myelogenous leukemia (CML). However, about 20% of patients treated in early chronic-phase CML are off therapy after 6 years because of resistance or intolerance, and most patients taking imatinib remain BCR-ABL-positive at the molecular level, indicating primary refractoriness of a leukemic subpopulation. Patients with advanced disease often do not respond, or they eventually relapse. Resistance frequently is associated with mutations in the kinase domain of BCR-ABL. Other mechanisms leading to reactivation of BCR-ABL or preventing sufficient BCR-ABL inhibition also exist. Resistance of patients with continued BCR-ABL inhibition despite leukemic progression indicates clonal evoluti... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=1411726 Tue, 29 Apr 2008 06:08:20 +0100 1411726 http://www.medworm.com/index.php?rid=1411729&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk611k04462156366%2F Abstract  Multiple myeloma remains incurable despite the use of high-dose therapy and autologous stem cell transplantation and the introduction of novel agents with high response rates. The use of an uncontaminated stem cell graft and the presence of a graft-versus-myeloma effect led to the use of allogeneic stem cell transplantation in myeloma, and it has been part of the therapeutic armamentarium for more than a decade. Early results were discouraging due to high transplantation-related mortality and high rates of graft-versus-host disease. More recently, better supportive care, increasing experience with this modality and its complications, use of reduced-intensity conditioning regimens, and its use earlier in the course of disease have led to improved outcomes. Patients ... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=1411729 Tue, 29 Apr 2008 06:08:19 +0100 1411729 http://www.medworm.com/index.php?rid=1195804&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc032610322234327%2F Content Type Journal ArticleDOI 10.1007/s11899-008-0001-2 Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211 Journal Volume Volume 3 Journal Issue Volume 3, Number 1 / January, 2008 (Source: Current Hematologic Malignancy Reports) Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=1195804 Thu, 31 Jan 2008 15:46:10 +0100 1195804 http://www.medworm.com/index.php?rid=1195801&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv5444h5300622n71%2F Abstract  Primary eosinophilic disorders include hypereosinophilic syndrome (HES); chronic eosinophilic leukemia, not otherwise categorized (CEL-NOC); platelet-derived growth factor receptor (PDGFR)-rearranged myeloid neoplasms; and other myeloid malignancies associated with prominent blood eosinophilia. According to the World Health Organization consensus criteria, the diagnosis of HES requires the absence of clonal cytogenetic or molecular markers of an underlying myeloid or lymphoid neoplasm. CEL-NOC constitutes an HES-like phenotype associated with an abnormal karyotype or excess blasts in blood (> 2%) or bone marrow (> 5%). HES and CEL-NOC are considered distinct from molecularly defined eosinophilic disorders, such as those associated with activating mutations o... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=1195801 Thu, 31 Jan 2008 15:46:10 +0100 1195801 http://www.medworm.com/index.php?rid=1195806&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F46327315l5584427%2F Abstract  Chronic myelomonocytic leukemia is a heterogeneous hematologic malignancy classified among the mixed myelodysplastic/myeloproliferative diseases by the World Health Organization because of its myelodysplastic and myeloproliferative characteristics. In the proliferative form, diagnosis should include screening for known molecular abnormalities associated with constitutively active tyrosine kinases, which may be candidates for targeted therapies. Because patient life expectancy is highly variable and there is no consensus on optimal therapy, clinicians are advised to rely on a specific risk-oriented scoring system for clinical decision-making for individual patients. Although supportive care represents the milestone for disease management, novel active agents such a... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=1195806 Thu, 31 Jan 2008 15:46:09 +0100 1195806 http://www.medworm.com/index.php?rid=1195803&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk817658928674732%2F Abstract  Myelodysplastic syndromes (MDS) are often associated with autoimmune processes that contribute to the cytopenias that characterize this disease group. Ten years ago, several investigators described improvement in the cytopenia of MDS following immunosuppressive treatments (IST) with antithymocyte globulin or cyclosporine. These findings have since been widely confirmed. The consensus is that about 30% of unselected transfusion-dependent patients with MDS given IST have sustained hematologic responses and can regain transfusion independence. Over the past decade, prognostic features have been defined that accurately identify the subset of patients most likely to benefit from IST. With increasing knowledge about the pathophysiology of myelosuppression in MDS, we are... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=1195803 Thu, 31 Jan 2008 15:46:09 +0100 1195803 http://www.medworm.com/index.php?rid=1195800&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu7178665g3280l6t%2F Abstract  Increased understanding of the biologic and clinical parameters that define subgroups of myelodysplastic syndromes has led to continuing refinement of classification strategies for diagnostic and prognostic use. The French-American-British classification, based primarily on morphology, was modified by the World Health Organization system to include the negative impact of multilineage dysplasias and higher blast counts. In addition, this system identifies a distinct clinical subgroup characterized by an isolated chromosome 5 deletion. The International Prognostic Scoring System was created to calculate prognosis, risk of transformation to acute myeloid leukemia, and median survival times. However, therapeutic decisions cannot be solely guided by these systems, and ... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=1195800 Thu, 31 Jan 2008 15:46:09 +0100 1195800 http://www.medworm.com/index.php?rid=1195807&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb73410348p1r5483%2F Abstract  New treatment approaches have substantially improved response rates in chronic lymphocytic leukemia. Accurate assessment of effective combination chemoimmunotherapy requires more sensitive measures of response, and a variety of techniques to measure minimal residual disease (MRD) have been developed. Because many studies demonstrate that MRD eradication is associated with prolonged treatment-free survival, detection of MRD is becoming a standard component of clinical trials. Quantitative approaches using polymerase chain reaction or multiparameter flow cytometry are preferable because they allow comparison of efficacy between different studies. In most clinical settings, the levels of chronic lymphocytic leukemia always increase from the first detection of MRD; th... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=1195807 Thu, 31 Jan 2008 15:46:08 +0100 1195807 http://www.medworm.com/index.php?rid=1195805&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fj36046mk83j77t57%2F Abstract  Although fludarabine-based regimens and monoclonal antibodies are able to induce high overall and complete remission rates in patients with chronic lymphocytic leukemia (CLL), a major impact on overall survival or even potential cure by these treatments is still lacking. Increased sensitivity and specificity of flow cytometry and polymerase chain reaction techniques enable us to detect few CLL cells in peripheral blood and bone morrow. This has brought significant advancement into the evaluation of response quality of CLL treatment. The eradication of minimal residual disease (MRD) below measurable levels seems to be critical to overcome recurring clonal expansion resulting in disease progression or relapse. Several studies suggest that achieving MRD negativity in... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=1195805 Thu, 31 Jan 2008 15:46:08 +0100 1195805 http://www.medworm.com/index.php?rid=1195802&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft04tw132430t4p63%2F Abstract  Angiogenesis has been shown to play a pivotal role in the growth and metastasis of solid tumors. Numerous in vitro and translational research studies have implicated a role for angiogenesis in the pathogenesis of myelodysplastic syndrome (MDS). Although the role of angiogenesis inhibitors in the treatment of solid tumors has evolved significantly over the past 5 years, their role in the treatment of hematologic malignancies such as MDS remains investigational. MDS treatment historically has been challenging, but the US Food and Drug Administration in the past 4 years has approved the hypomethylating agents 5-azacitidine and decitabine and the immunomodulatory agent lenalidomide for the 5q-syndrome. These approvals highlight recent successes in identifying and targ... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=1195802 Thu, 31 Jan 2008 15:46:08 +0100 1195802 http://www.medworm.com/index.php?rid=1195799&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F34h30424627x1372%2F Abstract  Myelodysplastic syndromes (MDS), or myelodysplasia, are a heterogeneous group of bone marrow disorders characterized by progressive cytopenias and a propensity to evolve into acute leukemia. The only curative strategy in the treatment of MDS is stem cell transplantation. The advent of hypomethylating agents and, more recently, lenalidomide has changed the paradigm so that supportive treatment for patients who are not candidates for transplantation now includes drugs that may alter the natural history of the disease. The remarkable results observed with lenalidomide in patients with del(5q) has promoted intense research into the pathobiology of MDS and new approaches to treatment; it is hoped that this success will be extended to all subtypes of patients with MDS. ... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=1195799 Thu, 31 Jan 2008 15:46:08 +0100 1195799 http://www.medworm.com/index.php?rid=991727&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb506174t40266k43%2F Abstract  Richter’s syndrome (RS) is the development of high-grade non-Hodgkin’s lymphoma (NHL) in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. This process may be triggered by viral infections (eg, Epstein-Barr virus infection), which are common in immunosuppressed patients. The large cells of RS either arise through a transformation of the original CLL clone or, less frequently, represent a new or secondary neoplasm. Karyotypic changes, including trisomy 12, chromosome 11 abnormalities, and multiple cell-cycle regulator disruptions, have been found in patients with RS. Although these genetic defects are believed to cause CLL cells to proliferate and, by facilitating the acquisition of new genetic abnormalities, to transform into RS c... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=991727 Sat, 27 Oct 2007 17:41:52 +0100 991727 http://www.medworm.com/index.php?rid=991726&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa3qk215074433q00%2F Abstract  Myeloablative allogeneic stem cell transplantation carries the promise of long-term disease control by graft-versus-lymphoma (GVL) immunity but is associated with a 30% to 40% risk of transplant-related mortality. Nonmyeloablative stem cell transplantation (NST) aims to exploit the GVL effect without the attendant toxicity of myeloablative conditioning. At the M.D. Anderson Cancer Center, the standard NST conditioning regimen for patients with follicular lymphoma is fludarabine, cyclophosphamide, and rituximab (FCR). Using this regimen, transplant-related mortality is currently 10%, and 85% of patients remain alive without disease at 3 to 4 years. This review discusses the current issues in NST for follicular lymphomas, including the optimization of conditioning i... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=991726 Sat, 27 Oct 2007 17:41:52 +0100 991726 http://www.medworm.com/index.php?rid=991725&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F3t143370l58071g1%2F This article discusses a number of recent treatments including antiretroviral therapy, aggressive chemotherapy, and allogeneic bone-marrow transplantation, as well as new drugs. Content Type Journal ArticleDOI 10.1007/s11899-007-0035-xAuthors Renaud MahieuxAntoine Gessain, Unité d’Epidémiologie et Physiopathologie des Virus Oncogènes, CNRS URA 3015 Department of Virology, Institut Pasteur 28 Rue du Dr Roux 75724 Paris Cedex 15 France Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211 Journal Volume Volume 2 Journal Issue Volume 2, Number 4 / October, 2007 (Source: Current Hematologic Malignancy Reports) Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=991725 Sat, 27 Oct 2007 17:41:52 +0100 991725 http://www.medworm.com/index.php?rid=991723&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft37451456m323gwg%2F Abstract  Prognostic markers identify subgroups of patients with similar risk profiles, helping to guide clinical care. The addition of rituximab to conventional anthracycline-based chemotherapy has improved clinical outcomes for patients with diffuse large B-cell lymphoma (DLBCL). Studies suggest that rituximab eliminates or modulates the significance of some markers (eg, BCL6 or BCL2), whereas other previously unimportant markers may emerge as significant prognostic indicators in the setting of treatment that now includes rituximab. These changes in the prognostic profile are likely to reflect the impact of rituximab on survival pathways important to some groups of patients with DLBCL but not to other groups, and thereby may provide clues to the underlying biology of the ... Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=991723 Sat, 27 Oct 2007 17:41:52 +0100 991723 http://www.medworm.com/index.php?rid=991721&cid=s_35935_19_f&fid=35935&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu6338712m5106x2g%2F Content Type Journal ArticleDOI 10.1007/s11899-007-0028-9 Journal Current Hematologic Malignancy ReportsOnline ISSN 1558-822XPrint ISSN 1558-8211 Journal Volume Volume 2 Journal Issue Volume 2, Number 4 / October, 2007 (Source: Current Hematologic Malignancy Reports) Current Hematologic Malignancy Reports journals http://www.medworm.com/rss/comments.php?id=991721 Sat, 27 Oct 2007 17:41:52 +0100 991721